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ABSTRACT 
 
NEAL R RASMUSSEN: Elucidating the role of the receptor tyrosine kinase Ror2 
within the Wnt pathway and its contributions to renal cell carcinoma tumorigenesis 
(Under the direction of W. Kimryn Rathmell, MD, PhD) 
Ror2, an important mediator of Wnt signaling cascades, has been shown to be 
aberrantly expressed in RCC promoting cell migration, invasion, and tumor growth. In this 
work, our goal was to elucidate the role of Ror2 as a Wnt receptor within its contextual 
expression of RCC. Utilizing microarrays we examined gene expression in RCC tumors and 
found Ror2 was significantly correlated with expression of several Wnt signaling genes 
including the classical feedback target gene, Axin2. Subsequent analysis in RCC cells 
showed that Ror2 expression results in a poised state for canonical Wnt signaling through 
an increased signaling pool of β-catenin, leading to an enhancement of target genes 
following Wnt3a stimulation. In addition, we utilized siRNA and dickkopf to inhibit LRP6 in 
order to show that Ror2 stabilization of β-catenin was independent of LRP6 but required for 
the downstream response to Wnt3a. Finally, we also saw that the Ror2 kinase domain is 
required for stabilization of soluble β-catenin and enhancement of canonical signaling. 
Due to Ror2’s correlation with aggressive disease in several cancers we have aimed 
to examine its contributions to cell migration and tumor growth, and its potential as a 
prognostic biomarker for RCC. Utilizing RCC cells and human tumors we have shown that 
both MMP2 and SFRP2 exhibit a significant correlation with Ror2. We show that Ror2 
expression results in increased cell migration that is dependent upon an intact Ror2 kinase 
domain. We also examined the effects of Ror2 overexpression in xenografts and found that 
Ror2 expression results in increased tumor growth and vascularity. To ascertain the 
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potential of Ror2 as a prognostic biomarker we first examined Ror2 expression in relation to 
the ccA and ccB molecular subtypes in RCC tumors, finding that Ror2 expression was 
significantly higher in ccB. Finally we assessed Ror2’s potential as an independent 
prognostic biomarker for RCC; we show that high Ror2 expression correlates with increased 
tumor growth and significant reduction in overall survival. These results exhibit Ror2’s 
potential as a prognostic biomarker and therapeutic target for RCC. 
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Chapter One 
INTRODUCTION 
 
Renal cell carcinoma 
Renal cell carcinoma (RCC) is a common epithelial tumor that continues to rise in 
prevalence in the face of recent advances in its treatment.  It is the sixth most commonly 
diagnosed cancer in men and the eighth most common in women. Though the cause of the 
disparity of incidence rates between the genders is as yet undetermined, men are twice as 
likely to develop RCC as women. It is estimated there will be over 65,000 new cases and 
13,000 deaths in the United States in 2013, nearly one-third of these new cases presenting 
with advanced RCC (1). For those patients with metastases upon diagnosis, the 5-year 
survival rate is bleak at less than 10% (2). Moreover, advanced RCC is quite difficult to treat 
because it is highly unresponsive to traditional single-agent or combination 
chemotherapeutic strategies. While cytokine therapies have consistently shown promise for 
a small subset of patients, the overall toxicity of current cytokine therapies interferes with 
their widespread use(3). 
RCC consists of several distinct histological subtypes including chromophobe, 
papillary, and clear cell renal cell carcinoma (ccRCC). ccRCC accounts for 70-75% of RCC 
cases and derives its name from its histologically characteristic clear cytoplasm, setting it 
apart from the other subtypes (4). The clear cytoplasm is due to ccRCC’s highly glycolytic 
 
(This work is modified from Rasmussen and Rathmell, Current Clinical Pharmacology, 2011) 
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and vascular nature, which results in a buildup of glycogens and lipids within the cytoplasm. 
All subsequent work and discussion presented here will focus solely on ccRCC, being 
referred to as either ccRCC or RCC. 
VHL/HIF signaling in clear cell renal cell carcinoma 
ccRCC is molecularly characterized by inactivation of the von Hippel-Lindau tumor 
suppressor gene (VHL), leading to constitutive stabilization of the hypoxia-inducible factors 
(HIF-1α and HIF-2α) (5). This feature is seen both in sporadic ccRCC and in patients with 
VHL syndrome, as a result of either biallelic mutations or functional inactivation of the VHL 
protein (pVHL) in 75-85% of ccRCC cases (6-9). Under normoxia or normal oxygen 
conditions, pVHL serves as part of the E3 ubiquitin ligase complex that recognizes 
hydroxylated prolyl residues of HIFα subunits mark them for proteasomal degradation. 
However, under hypoxic conditions or when pVHL is inactivated, the HIFα subunits 
accumulate and heterodimerize with HIF-1β (ARNT), translocating into the nucleus and 
regulating transcription of target genes. The skewed VHL/HIF axis seen in ccRCC results in 
increased expression of a variety of hypoxia-inducible genes shared by both HIF-1α and 
HIF-2α including the pro-angiogenic factors platelet-derived growth factor (PDGF) and 
vascular endothelial growth factor (VEGF), the extracellular matrix (ECM) remodeling protein 
matrix metalloprotease 2 (MMP2), and glucose transporter 1 (Glut1)  (Figure 1.1). Although 
HIF-1α and HIF-2α are highly similar, with 48% overall amino acid identity, they exhibit 
unique expression profiles and induction of distinct target genes (10). HIF-1α-targeted 
induction of lactate dehydrogenase-A (LDA) and phospho-glycerase kinase (PKA) are 
representative of the increased metabolic activity observed in RCC. However, HIF-2α 
expression, can increase in-vivo tumor growth in RCC cells when acting alone, uniquely 
targets erythropoietin, Cyclin D1 (CCND1), and Oct-4, an important factor in stem cell 
regulation and de-differentiation (11,12).  
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In addition to its function as part of the E3 ubiquitin ligase complex regulating HIF, 
pVHL has been shown to regulate cell cycle, apoptosis, fibronectin binding, and extracellular 
matrix assembly, independent of HIF (13-18). The established hallmarks of cancer include 
the escape of programmed cell death and cell cycle checkpoints leading to sustained cell 
proliferation (19). As previously noted, traditional therapeutics have had limited efficacy in 
RCC because of its resistance to radiotherapy and cytotoxic treatments. These features of 
RCC may be partially attributed to increased anti-apoptotic signaling within the tumor. The 
contribution of loss of pVHL to these tumorigenic signaling networks is well illustrated by its 
regulation of several proteins known to be central to these cellular processes. 
The tumor suppressor p53 serves as a key regulator of cell cycle and has been 
observed to be mutated in a significant portion of solid tumors. While many studies have 
noted the distinct lack of p53 mutations in RCC (6), pVHL has been shown to directly 
associate with p53, inhibiting Mdm-2 ubiquitination and the promotion of its transactivation. 
The loss of pVHL and proper regulation of p53 in RCC cells results in attenuated apoptosis 
or abnormal cell cycle arrest upon DNA damage (15). pVHL also serves as a negative 
regulator of the transcription factor nuclear factor κB (NFκB) through inhibitory 
phosphorylation of the NFκB agonist Card9 (20,21). Thus the loss of pVHL drives RCC 
tumorigenesis through the resulting increased anti-apoptotic signaling and improper cell 
cycle control. Finally, pVHL has been found to bind and inhibit atypical protein kinase C 
(aPKC) which is associated with cell proliferation, cellular survival, and in establishment and 
maintenance of cell-cell junctions (22,23). 
 Another hallmark of cancer is the ability of tumor cells to migrate and invade, 
allowing the cancer to metastasize throughout the body (19). Critical to cells’ ability to do 
this is the loss of cell-cell adhesion, along with the remodeling of the surrounding ECM, 
which normally acts as a structural support for cells. pVHL has been shown to directly bind 
and play a crucial role in the regulation of fibronectin matrix assembly (17,18). pVHL also 
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requires the ECM to mediate cell signaling,as removal of the ECM substrate in-vitro, results 
in a reduction of epithelial differentiation and growth arrest at high cell density (16). 
Correlating with these changes in epithelial differentiation, pVHL loss in RCC cells results in 
an epithelial-mesenchymal transition (EMT) marked by decreased expression of epithelial 
markers that promote cellular adhesion (e.g. E-cadherin and γ-catenin) and accompanying 
increased expression of N-cadherin, vimentin, integrins, MMP2, and MMP9 characteristic of 
motile mesenchymal cells (21,22). Reintroduction of VHL expression or inhibition of NFκB in 
VHL null cells is also capable of reverting expression of these EMT markers in RCC cells 
(21). Taken together, these findings coalesce into a clearer understanding of how loss or 
inactivation of VHL drives many aspects of RCC tumor biology including resistance to 
traditional therapies, tumor initiation, and tumor progression. 
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RCC targeted therapeutic development  
Better understanding of the molecular underpinnings of RCC has led to the advent of 
the use of targeted therapies such as the anti-angiogenic VEGF and PDGF receptor 
tyrosine kinase inhibitors sorafenib (Nexavar, Bayer/Onyx), pazopanib (Votrient, Glaxo 
Smith Kline) and sunitinib (Sutent, Pfizer), and the VEGF-neutralizing antibody bevacizumab 
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(Avastin, Genentech) (24-28). Each of these compounds has contributed significantly to 
improving the progression-free survival of patients with RCC, thus advancing the standard of 
care for the disease. Two mTOR inhibitors, temsirolimus (Torisel, Wyeth), and everolimus 
(Afinitor, Novartis) have also shown clinical efficacy in the care of advanced RCC, with 
temsirolimus extending overall survival for patients with extremely poor-risk disease (29,30). 
Despite the progress seen with the introduction of these targeted therapies, there 
remains considerable room for improvement, considering that no available targeted 
therapies are currently capable of inducing remission, and de novo or acquired resistance to 
these targeted therapies is an on-going challenge facing clinicians. Further complicating 
matters, several of the currently approved therapies exhibit undesirable and dose-limiting 
side effects due to toxicity, most likely on account of both on- and off-target effects. Given 
the limitations of current targeted therapies there is a great need in the field for more targets 
for development of therapeutics for use as first-line agents or in combination with available 
therapies. 
Because loss of VHL is one of the defining molecular characteristics of RCC, its 
interactions in the disease have been well characterized. As mentioned above, upon loss or 
inactivation of pVHL the HIF subunits accumulate and lead to the transcriptional induction of 
various target genes including VEGF and PDGF (Figure 1.1) (31). The molecular targeted 
therapies described above were designed to take advantage of this aspect of VHL 
deficiency, and are thought to primarily affect the VEGF and PDGF receptor tyrosine 
kinases expressed on tumor-supporting endothelial cells and pericytes. The efficacy of 
these drugs in inducing disease response and stabilization implicates this pathway as one 
important to the maintenance of renal tumors. Promising new targets exist at an array of 
points all along the VHL-HIF axis which could possibly address the problems of side effects 
and acquired resistance to VEGF-receptor targeted therapies. 
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Potential therapeutic targets in VHL/HIF signaling in RCC 
The most immediate potential targets for therapeutics are the HIF transcription 
factors themselves, with HIF-2α expression being sufficient to induce in-vivo tumor growth 
(12). Various efforts have focused on targeting one or both HIF factors, with initial strategies 
directed toward the first of these factors to be characterized, HIF-1α. Transcription factors 
are notoriously difficult to inhibit compared to targets with enzymatic activity. Even so, 
strategies aimed at reducing the production or stability of these factors can be effective. HIF-
1α is regulated by a variety of mechanisms in addition to the E3 ubiquitination provided via 
it’s interaction with pVHL. These include the phosphatidylinositide 3-kinase (PI3K)/mTOR 
pathway, mitogen activation protein kinase (MAPK) signaling, and other autocrine circuitry 
(32). Agents intersecting all of these signaling pathways are presently in development for 
RCC and other tumor types and need to be evaluated in the context of ccRCC. 
Several unique approaches have been undertaken to therapeutically reduce HIF-1α 
levels. EZN-2968, has highlighted the potential of antisense oligos, as it is able to effectively 
reduce both HIF-1α and target gene expression in-vitro and in-vivo (33) (Table 1.1). 
Oxygen-independent stablization of HIF-1α is also mediated by heat shock protein 90 
(HSP90), providing an alternate target which has shown significant promise in reducing HIF-
1 levels in the setting of VHL loss, and is currently being evaluated in clinical trials (34-36). 
YC-1 (3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole), originally identified as agent-targeting 
cyclic GMP, has been found to exhibit activity in repressing HIF-1α and to inhibit tumor 
growth (37). The small molecule inhibitor PX-478 (S-2-amino-3-(4’-N,N,-bis(2-
chloroethyl)amino) phenyl propionic acid N-oxide dihydrochloride) has been shown to inhibit 
translation of HIF-1α and to exhibit antitumor activity (38,39). Other mechanisms also 
modulate HIF-1α production, but they are not as well understood. For example, one group 
has demonstrated a direct effect of treatment with the antihelmenthic agent albendazole on 
8 
 
tumor cell HIF-1α levels (40). These demonstrate some unique and upcoming inhibitors to 
HIF-1α; a more comprehensive review of all potential inhibitors can be found here (41). 
Because several reports have suggested a primary role for HIF-2α in promoting 
ccRCC tumorigenesis, HIF-2α has begun to set itself apart as the more promising 
therapeutic target for pharmaceutical development. HIF-2α may in fact provide an essential 
function in ccRCC, and thus emerge as the key target. Recent studies inhibiting HIF-2α in 
VHL-null cells resulted in inhibition of cell growth (42,43). In vitro and in vivo experiments 
have further shown that stable expression of HIF-2α can drive tumor growth even in the 
presence of pVHL (12,44,45). Finally, examination of ccRCC tumors reveals that these 
tumors either express HIF-2α exclusively (H2 tumors) or HIF-2α along with HIF-1α (H1H2 
tumors), leaving HIF-2α expression as the common denominator of VHL-mutated cancers 
(46). Thus, the evidence that HIF-2α is possibly a driving force in RCC tumorigenesis sets it 
apart as a promising target. 
Less is understood about the regulation of HIF-2α, but efforts to target this factor are 
rapidly emerging from in vitro studies. One intriguing compound, emetine, is a protein 
synthesis inhibitor that has been shown to specifically inhibit HIF-2α protein stability in the 
setting of VHL loss, although the effect of sustained treatment with emetine in functional 
tumor assays remains unknown (47) (Table 1.1). An alternate class of inhibitors has shed 
light on the transcriptional regulation of HIF-2α. In a screen for small molecules to blunt HIF-
2α transcription, the identified compounds enhance the binding of iron-regulatory protein-1 
(IRP1) to an iron-responsive element in the HIF-2α 5’-untranslated region, effectively 
suppressing transcription of HIF-2α (48). This novel approach provides an effective strategy 
to limit HIF-2α accumulation, but remains to be studied in in vitro or in vivo assays of 
tumorigenesis. 
These opportunities to effectively reduce the HIF transcriptional signal might be 
considered a strategy that would supplant VEGF or VEGF receptor inhibition, considering 
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the seeming linearity of these events. However, preliminary evidence suggests that 
removing the powerful stimulus of HIF transcriptional signals on a broad array of pro-
angiogenic and other factors may enhance the activity of VEGF pathway-directed agents. 
This interesting pre-clinical observation heralds important considerations for ccRCC clinical 
trial design using vertical combination inhibitory strategies. 
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Table 1.1 Stage of development for new targeted therapies for RCC 
 
Agent Drug Class Target Developmental Stage Study 
HIF 
EZN-2968 Anti-sense oligo HIF-1α Phase1 (33) 
PX-478 Small molecule HIF-1α In Vitro/In Vivo (38) 
albendazole Small molecule HIF-1α In Vitro (40)
YC-1 Small molecule cGC/HIF-1α In Vitro/In Vivo (37) 
17-AAG Small molecule HSP-90/HIF-1α Phase II (36)
emetine Small molecule HIF-2α In Vitro (47)
compound 76 Small molecule HIF-2α In Vitro (48)
HIF-Targets 
cG250 AB CAIX Phase I/II (49) 
compound 7 Small molecule Tie-2 In Vitro/In Vivo (50)
AMG 386 AB Ang-1/2 Phase I/II (51)
PI3K/mTOR 
XL147 Small molecule PI3K Phase I/II (52)
NVP-BKM120 Small molecule PI3K Phase I (53)
XL765 Small molecule PI3K/mTOR Phase I/II (54)
NVP-BEZ235 Small molecule PI3K/mTOR Phase I (55) 
GSK2334470 Small molecule PDK1 In Vitro (56,57) 
AR-12 Small molecule PDK1 Phase I (56,57) 
Palomid 529 Small molecule mTORC1/2 In Vitro/In Vivo (58)
OSI-027 Small molecule mTORC1/2 In Vitro/In Vivo (59)
PP-242 Small molecule mTORC1/2 In Vitro/In Vivo (60)
AZD-8055 Small molecule mTORC1/2 In Vitro/In Vivo (61)
HIF, hypoxia-inducible factor; cGC, cyclic GMP; HSP-90, heat shock protein-90; AB, 
antibody; CAIX, carbonic andhydrase; Ang, Angipoietin; PI3K, phosphatidylinositol 3-kinase; 
mTOR, mammalian target of rapamycin; PDK1, phosphoinositide dependent protein kinase 
1, mTORC, mTOR-containing complexes 
  
11 
 
Developing targeted therapies for downstream HIF targets 
In addition to targeting the HIF transcription family members themselves, HIF factors 
promote the transcription of over 100 immediate targets and innumerable secondary targets. 
In terms of broad classification, this spectrum of targets provides the opportunity to 
selectively inhibit angiogenesis with current or new putative targets, interfering with HIF-
mediated cell growth and apoptotic resistance, impacting cell migration and extracellular 
matrix regulation, and finally identifying novel ways to harness altered cellular metabolism. A 
few selected targets downstream of HIF stabilization have already begun to present 
particularly intriguing possibilities for therapeutic development in RCC (Figure 1.1). 
Carbonic anhydrase IX (CAIX) is one of many hypoxia-inducible target genes, but is 
unique in that it is found to be highly expressed in many ccRCC tumors (62). Due to these 
high expression levels, CAIX in RCC is now being pursued as a prognostic indicator, 
diagnostic tool, and prospective target for chemotherapeutics. CAIX serves a regulator for 
maintaining the pH in the cell and the microenvironment surrounding the cell (63,64). 
Strategies have emerged utilizing anti-CAIX antibody (also known as cG250) to identify 
tumors which are highly expressive of this moiety using molecular directed nuclear imaging 
(49). As a highly expressed cell surface marker in RCC, this antibody has also been 
investigated as a therapeutic modality to target agents more effectively to the tumor or as an 
agent with direct antitumor activity in the context of a large placebo-controlled adjuvant 
study (Table 1.1). 
Anti-angiogenic therapies have become the standard of care for RCC due to its 
highly vascular nature and its resistance to traditional chemotherapeutic approaches, but 
resistance is common. Because this resistance appears to occur as a result of angiogenic 
escape mechanisms, expanding the repertoire of anti-angiogenic factors related to ccRCC is 
highly desirable. Additional angiogenic targets have been identified in RCC including the 
kinase Tie2 which serves as a receptor for the family of angiopoietin ligands, pro-angiogenic 
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targets of HIF transcriptional activity. Like other targeted angiogenic kinases, Tie2 
expression is mostly restricted to endothelial cells, but has been shown to correlate with 
angiopotietin-2 expression in RCC tumors (65). Being an enzymatically active kinase, 
conventional small molecule inhibitor screens have been effective in producing lead 
compounds (50) (Table 1.1). These have been shown in preclinical models to be effective at 
reducing aberrant tumor vessel growth. Several Tie2 inhibitors are being seriously 
considered for clinical trials as stand-alone anti-angiogenics, or as therapeutic options to 
combat VEGF receptor inhibitor resistance. Similarly, the inhibition of angiopoietins 
themselves provides another tractable anti-angiogenic strategy. Angiopoietins 1 and 2 
(Ang1, Ang2) are both targets and mediators of HIF expression (66). These molecules 
therefore present an interesting opportunity to dampen HIF expression while having a direct 
effect on tumor angiogenesis. One drug, a neutralizing peptibody, AMG 386 (Amgen) is 
currently being evaluated in clinical trials (51) (Table 1.1). These targets not only present 
possible new therapeutic options for the care of RCC patients but a unique opportunity to 
better understand the underlying biology of these tumors. Sequential or combinatorial 
therapies involving targeting Ang1, Ang2, and Tie2 also would serve to better understand 
the mechanisms of resistance in RCC, if it is through compensatory upregulation of HIF or 
simply engagement of untargeted angiogenic receptors among the endothelial cells. In 
addition, as Tie2 expression is limited solely to endothelial cells, as is thought to be the case 
for the angiogenic VEGF receptor, this presents an opportunity to examine the interplay 
between the tumor and the supporting microenvironment. 
PI3K/AKT/mTOR signaling in clear cell renal cell carcinoma 
VHL loss alone in mice has been unable to completely recapitulate the clinically 
observed pathology of ccRCC , therefore additional driver mutations and signaling cascades 
must play a role as well (67-69). The collaborative efforts found in the Cancer Genome Atlas 
(TCGA) have validated previous findings and identified genes in addition to VHL which 
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exhibit significantly high rates of mutation. Of note, two members of the mechanistic target 
rapamycin (mTOR) signaling cascade were included; mechanistic target of rapamycin 
(mTOR) and phosphatase and tensin homolog (PTEN) were among the eight most 
frequently mutated members (6). 
The mTOR signaling cascade serves as a major hub for signals from the 
extracellular milieu, regulating a variety of intracellular processes including metabolism, 
survival, protein and lipid synthesis, and autophagy (70). Mutations and misregulation within 
the mTOR signaling pathway are implicated in a wide spectrum of cancers. Initiation of the 
mTOR signaling cascade occurs through multiple receptor tyrosine kinases (RTK) including 
epidermal growth factor receptor (EGFR), insulin-like growth factor receptor (IGFR), and 
platelet-derived growth factor receptor (PDGFR) leading to activation of PI3K, which 
produces the secondary messenger phosphoinositol-3,4,5-triphosphate (PIP3) and is tightly 
regulated by the tumor suppressor PTEN. The resulting PIP3 recruits AKT (protein kinase B, 
PKB) to the membrane, where AKT is phosphorylated by phosphoinositide dependent 
protein kinase 1 (PDK1) to its fully activated form. The signaling cascade continues with 
activated AKT directly activating mTOR by phosphorylation and indirectly activating MTOR 
through inhibition of tuberous sclerosis 1 or 2 (TSC1/2), negative regulators of mTOR. 
Subsequent formation of either mTOR complex 1 (mTORC1) or mTOR complex 2 
(mTORC2), dependent upon the inclusion of either regulatory-associated protein of mTOR 
(Raptor) or Rapamycin-Insensitive companion of mTOR (Rictor) respectively, regulates a 
wide variety of cellular effects including cell growth, survival and angiogenesis (71) (Figure 
1.2). 
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Developing PI3K/AKT/mTOR pathway targeted therapeutics 
The PI3K/AKT/mTOR pathway represents a prime target for the development of 
therapeutics since it is one of the most common aberrant pathways activated in cancer, 
regulating many known oncogenic pathways including apoptosis, proliferation, and cell 
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migration (72,73). Capitalizing on the known effects of the mTOR pathway, mTORC1 
complex inhibitors have become an additional tool for treatment of advanced RCC (29,30) 
(Figure 1.2). Despite the initial successes of the mTOR inhibitors their efficacy has been 
limited, highlighting the need for additional therapeutic targets. 
Because PI3K serves as a bottleneck in response to several RTKs and is the most 
proximal element, it has become another attractive target for RCC to be used alone or 
concert with current mTOR inhibitors. Two prospective PI3K inhibitors, LY294002 and 
wortmannin, have been shown to decrease AKT activation and significantly reduce cell 
growth in vitro through induction of cell apoptosis. Use of the small molecule inhibitor 
LY294002 in vivo was able to induce tumor regression (74). Although LY294002 and 
wortmannin exhibit limited selectivity and high toxicity, they demonstrate the possibilities 
associated with inhibiting PI3K in RCC. Ongoing studies using PI3K and dual PI3K/mTOR 
inhibitors modified for clinical use are ongoing (52-55) (Table 1.1). 
Similar to PI3K, PDK1, a key mediator of AKT activation, is poised to respond to 
targeted inhibition by blockade of AKT signaling. Both highly specific inhibitors such as AR-
12 (Arno) and inhibitors with dual function on PDK1/PI3K or PDK1/AKT are in development 
(56,57) (Table 1.1). These targets present another possibly robust way to render the AKT 
pathway completely inhibited, mitigating the confounding issues of inhibition of each of the 
AKT family members. 
Upon phosphorylation AKT is known to interact with a large set of substrates, 
impacting many key cellular processes such as cell cycle progression and apoptosis, both of 
which execute a vital function in oncogenesis (75). In addition, AKT is constitutively 
activated in RCC cell lines (74). Recent work has suggested mTORC2 provides feedback to 
AKT, leading to its compensatory activation (76,77). AKT targeting via direct or indirect 
methods to impair its activation should prove to be effective therapy in RCC, given the high 
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expression of activated AKT, and as coordinate therapy with current mTOR inhibitors 
curbing possible refractory responses. 
mTOR performs a vital role in regulating critical cellular processes including cell 
growth, proliferation, transcription, and protein synthesis (78). In addition to the 
aforementioned effects of mTOR activation, mTOR plays an important part in regulating HIF-
1α expression. Targeting mTOR is already an FDA-approved strategy for the treatment of 
RCC but both rapalogs temsirolimus and everolimus suffer from the drawbacks of seeming 
to be solely selective for inhibiting mTORC1 and, as previously mentioned, can lead to 
upstream activation of AKT through mTORC2 (76,77). This highlights the need for targeted 
agents for mTORC2 or dual inhibitors of both mTORC1 and mTORC2. Inhibitors in these 
categories are also being developed for clinical use (58-61) (Table 1.1). 
Overcoming resistance in RCC 
A continuing impediment to the treatment of RCC in the clinic is resistance to 
established targeted therapies. The driving forces behind initial or developed resistance in 
RCC are not yet fully understood. However, RCC xenografts submitted to a daily regimen of 
the VEGF receptor inhibitor sorafenib showed a reduction in supporting tumor vasculature 
that was reestablished prior to the onset of resistance (79). These findings suggest a 
potential mechanism of resistance where, through either compensatory activity of the VEGF 
or alternative angiogenic pathways, the supporting vasculature to the tumor is reestablished 
(80). Several of the targets discussed above lend themselves as potential tools in 
overcoming and better understanding these mechanisms of resistance in RCC. 
As previously discussed, RCC is characterized by loss or inactivation of VHL, leading 
to constitutive stabilization of HIFα. A plausible mechanism for this observed resistance is 
through upregulation of HIF transcription factors and targeted pro-angiogenic genes VEGF 
and PDGF. If a compensatory increase in HIF levels is truly driving the development of 
resistance in RCC, targeting HIF either directly or indirectly through inhibition of the 
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PI3K/AKT/mTOR pathway may lead to renewed potentiation of VEGF-receptor targeted 
therapies. This approach was examined in colon cancer xenografts using the VEGF 
receptor inhibitor, sunitinib, with and without disruption of HIF-1α and HIF-2α, showing an 
additive effect on angiogenesis and tumor cell proliferation (81). Additionally, the use of 
mTOR inhibitors temsirolimus and everolimus has been shown to lead to a compensatory 
activation of AKT which could spur a resurgence of vasculature through an upregulation of 
HIF (76,77). Vertical combination approaches targeting PI3K, AKT, and PDK1 or use of 
inhibitors that more fully target both mTORC complexes pose an intriguing possibility that 
calls for further research. Another avenue for escape from treatment with the established 
anti-angiogenic therapies lies in additional angiogenic pathways independent of VEGF. One 
of these VEGF independent pathways, receptor Tie2 and ligands Ang1/2, has been 
discussed previously here as a new target for RCC. Inhibition of the kinase Tie2 and 
blocking of the angiopoietins or other adjunctive angiogenic signals offers a plausible route 
to more fully restrict the reestablishment of the supporting tumor vasculature. Further 
research using these strategies either in sequential or combination with available targeted 
therapies is needed to establish their efficacy in reducing resistance in RCC. 
 
Receptor tyrosine kinase, Ror2 
An exciting, novel RCC therapeutic target recently identified is the developmentally 
regulated receptor tyrosine kinase-like orphan receptor 2 (Ror2) which has been shown to 
be expressed in a VHL- and HIF-dependent manner in RCC (82,83). Ror2 is a member of 
the Ror family of receptor tyrosine kinases (RTK) which also includes Ror1. Ror1 and Ror2 
are both characterized by a conserved series of domains, including an Immunoglobin-like 
domain, a Frizzled-like cysteine-rich domain (CRD) allowing Ror RTK to serve as  Wnt 
receptors, and a kringle domain in their extracellular portion. The intracellular portion of Ror 
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RTK includes a tyrosine kinase domain, which shows a high degree of amino acid identity 
with both muscle-specific kinase (MuSK) and the tropomyosin receptor kinase (Trk), 
kinases, which served as the basis of the original identification of hRor1 and hRor2 genes in 
humans by PCR screen (84). Both the mouse and human orthologs of Ror RTK also include 
a series of domains following the tyrosine kinase domain, consisting of a proline-rich domain 
flanked on both sides by serine/threonine-rich domains. These serine/threonine-rich 
domains have been shown to be necessary for activity and mediating protein interactions 
(85-89). This general structure of domains is well conserved with a few deviations across 
species within the Ror othologs identified in A. californica (Apror) (90), C. elegans (CAM-1) , 
D. melanogaster (dRor) (91), X. laevis (xRor2) (92), into the split of two genes in M. 
musculus (mRor1, mRor2) (93), and humans (hRor1, hRor2) (84) (Figure 1.3). Although 
Ror1 and Ror2 share this overall conserved structure of domains they diverge in that overall 
they share only 58% amino acid identity. However, there is a 92% amino acid identity 
between mRor2 and hRor2, allowing studies in both to be reasonably used to inform one 
another. 
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Ror2 a developmental receptor tyrosine kinase 
The role of Ror2 as a developmental kinase was first evident in CAM-1 mutants, 
which exhibit improper cell migration, defects in asymmetric cell divisions, and axon 
outgrowth in C. elegans (94-96). These mutational analyses also highlight the function of 
Ror2 as a Wnt receptor, since overexpression of EGL-20 (a Wnt) phenocopies mutant CAM-
1 migration defects (97). Several independent knockout studies of mouse mRor1 and mRor2 
have further elucidated their expression patterns and roles in development. Ror2 expression 
is largely restricted to embryogenesis, with expression seen in the heart, brain, nervous 
system, lungs, midgut, developing limb buds, and kidney (83,93,98-105) although some 
limited expression of Ror2 has been observed in the adult within the cycling uterus, colon, 
and small intestine (106,107). 
Knockout of Ror2 results in perinatal lethality, most likely due to respiratory defects. 
Loss of Ror2 also results in widespread skeletal abnormalities, ventricular septal defects in 
the heart, and decreased branching of sympathetic neuron axons (93,98-102). Loss of 
mRor1, however, exhibits none of the developmental defects seen in mRor2, though 
mRor1/mRor2-null mice experience an increased severity of these developmental defects, 
suggesting some level of redundancy or interaction within Ror RTKs (100-102). The skeletal 
defects are the result of loss of Ror2 in proliferating chrondocytes, leading to reduced 
endochondral ossification (98,99). Many of the developmental defects observed in the 
mRor2 knockout are phenocopied in Wnt5a-null mice (108). In addition the spatiotemporal 
expression of Wnt5a and Ror2 during development overlaps in many tissues, including the 
facial primordia, limb mesenchyme, neural crest-derived tissues, and the genital tubercle 
(100,101,108). Together, these observations suggest that Ror2 may function as a receptor 
for Wnt5a during development. 
Due to the widespread skeletal defects observed in mRor2-null mice, it is 
unsurprising that mutations in hRor2 in humans have been linked to two skeletal 
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developmental disorders: recessive Robinow syndrome and autosomal dominant 
Brachydactyly type B (109-112). Robinow syndrome is characterized by skeletal dysplasia, 
limb foreshortening, brachydactyly, craniofacial malformations, and genital hypoplasia. 
These features are strikingly similar to the phenotypes observed in Ror2 knockout mice, 
suggesting that Robinow syndrome is indeed due to loss of Ror2. However, Brachydactyly 
type B effects are limited to hypoplasia of the distal phalanges and nails. The differences in 
Robinow syndrome and Brachydactyly type B phenotypes is reflected by the mutational 
profile of Ror2 for each. Robinow Syndrome is characterized by missense, nonsense, and 
frameshift mutations within the CRD, Kringle, and tyrosine kinase domains, resulting in loss 
of Ror2 function. However, the Ror2 mutations resulting in Brachydactyly type B are due to 
truncation of the protein within or after the kinase domain (112). 
Ror2 in Cancer 
In addition to its contribution during development, expression of Ror2 has been 
observed in an increasing array of cancers. Ror2 expression was first identified in SH-SY5Y 
cells derived from a neuroblastoma (84). The aberrant expression of Ror2 in primary human 
RCC tumors was initially shown in 2009, where its expression in RCC cells was found to be 
VHL- and HIF-dependent (82,83). Expression of Ror2 in RCC cells was shown to promote 
cell migration, anchorage-independent growth and in-vivo growth in xenografts (83). Since 
that time Ror2 expression has been observed in several other cancers including 
osteosarcoma, melanoma, prostate cancer, gastric cancer, gastrointestinal stromal tumor 
(GIST), leiomyosarcoma (LMS), and squamous cell carcinoma of the head and neck (113-
120) (Table 1.2). 
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Table 1.2: Summary of the role of Ror2 in various cancers 
Tumor promotion 
Cancer Reference Role of Ror2 
Osteosarcoma (114) Cell proliferation 
Cell invasion 
Wnt5b/Ror2 signaling 
  (113) Cell migration 
Cell invasion 
Formation of invadapodia 
Wnt5a/Ror2 Signaling 
MMP13 expression 
  (121) Correlates with disease severity 
Melanoma (122) Correlates with metastasis 
Cell migration 
Cell invasion 
Pulmonary metastasis formation 
Wnt5a/Ror2 signaling 
 (89) Higher expression in metastatic cells 
GIST and LMS (116) Correlates with decreased survival 
Cell invasion 
Xenograft tumor growth 
Renal cell carcinoma (83) Cell migration 
Anchorage independent growth 
Xenograft tumor growth 
MMP2 expression 
Prostate (118) Cell migration 
Cell invasion 
Ror2/Wnt5a signaling 
MMP1 expression 
Gastric Cancer (119) Ror2 mutated in activation domain 
 (120) Cell invasion 
Head & Neck (117) Correlates with disease malignancy 
Cell motility 
Cell polarity 
 
Tumor suppression 
Cancer Reference Role of Ror2 
Head & Neck (123) Decreased Ror2 expression 
Colorectal 
  
  
  
(124) Ror2 methylation 
Decreased Ror2 expression 
Cell viability 
Colony formation 
Xenograft tumor growth 
Wnt5a/Ror2 signaling 
Hepatocellular (125) Decreased Ror2 expression 
Correlates with shorter overall 
survival 
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Since changes in Ror2 expression result in drastic defects in skeletal development, it 
is fairly unsurprising to find the reexpression of Ror2 in osteosarcoma, a malignant 
adolescent bone cancer. In-vitro analysis shows aberrant expression of Ror2 in 
osteosarcoma increases cell proliferation, migration, invasion, and formation of invadapodia 
(113,114). These invasive and migratory characteristics are mediated by Ror2-dependent 
expression of the extracellular matrix remodeling protease, matrix metalloprotease 13 
MMP13 (113,114,126). Surprisingly, either Wnt5a or Wnt5b in connection with Ror2 were 
able to mediate these aggressive features in osteosarcoma cells. An analysis of primary 
osteosarcoma tumors through IHC for Wnt5a and ROR2 revealed a positive correlation 
between their high degree of expression in over 70% of samples. In addition, both Wnt5a 
and Ror2 correlated with Enneking surgical stage and tumor metastasis. These findings 
further confirm the role of Ror2 in tumor progression in osteosarcoma and its potential as 
prognostic biomarker (121). 
Previous works elucidating the process of tumor metastasis in melanoma have 
shown Wnt5a to be overexpressed in metastatic melanoma tissues and correlated with 
decreased survival in melanoma patients (127,128). In addition to Wnt5a’s role in promoting 
tumor progression and metastasis in melanoma, it also serves in regulating Ror2 expression 
in melanoma cells. Utilizing in-vitro and in-vivo approaches, suppression of Wnt5a/Ror2 
signaling resulted in decreased cell invasion, migration, and metastasis (122). Reflective of 
the shared role Wnt5a and Ror2 have exhibited in melanoma, Ror2 is similarly correlated 
with metastasis (89,122).  
Soft-tissue sarcomas are heterogeneous malignant tumors that currently have limited 
therapeutic options and prognostic biomarkers. Edris et al. undertook an analysis using a 
library of sarcomas to uncover novel RTK targets or biomarkers (116). Ror2 expression was 
detected in both LMS and GIST utilizing both gene expression and IHC as validation. 
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Knockdown of Ror2 reduced cell invasion in both GIST and LMS cells. Similar to our 
previous finding in RCC cells (83), suppression of Ror2 in LMS significantly reduced in-vivo 
tumor growth. Finally, Edris et al. showed that Ror2 can serve as an independent prognostic 
factor for both LMS and GIST, with Ror2 expression predicting poorer clinical outcome 
(116). 
For most prostate cancer patients the rate of response to treatment is high if the 
disease is caught in its early stages. However for the 20-30% of patients that experience 
recurrence the picture is much more grim highlighting the need for identification of novel 
biomarkers to predict recurrence and identify new therapeutic targets. Yamamoto et al. 
showed that Wnt5a expression correlates with high Gleason scores, which are linked to 
increased risk of recurrence. Suppression of Ror2 resulted in decreased Wnt5a-dependent 
cell migration and invasion in prostate cancer-derived cells. These invasive characteristics 
are partially mediated by MMP1 in a Wnt5a/Ror2 dependent signaling manner (118).  
An analysis undertaken to identify additional RTK targets expressed in gastric cancer 
screened all RTKs for mutations within the kinase domain in a series of gastric cancer cell 
lines and 52 microdissected primary gastric cancer tumors. Ror2 was identified among other 
RTKs to be expressed in poorly-differentiated invasive gastric cancers and to be a frequent 
target of non-synonymous mutagenesis. The identified D644N mutation is found within the 
kinase domain of Ror2, likely altering activity of the RTK Ror2. The indication that Ror2 is a 
potential driving factor in the development and/or progression of RCC is strengthened by the 
combined weight of these studies with similar suggestive correlations between increased 
invasive malignancy and Ror2, marking it as a promising therapeutic target. These studies 
also emphasize the potential of Ror2 as a prognostic and/or diagnostic biomarker. 
Conflicting reports on whether Ror2 is more highly expressed in squamous cell 
carcinoma have been published. Kobayashi states that Ror2 is more highly expressed in 
comparison to normal tissue and is linked to cell polarity, motility, and increased malignancy 
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(117), but Liu et al. states that Ror2 expression is downregulated in comparison to adjacent 
corresponding normal tissues (123). Seeing that both studies rely upon very small sample 
sizes, any firm conclusions cannot be made at this time and further studies are required to 
clarify this discrepancy. 
This ambiguity is further reflected in Ror2’s purported tumor-suppressive capacity in 
both colorectal cancer and hepatocellular carcinoma. Epigenetic silencing of Ror2 through 
hypermethylation was observed in both colorectal cancer-derived cell lines and in primary 
tumors, with rescue of Ror2 inhibiting in-vitro and in-vivo tumor growth (129). Similarly 
reduced Ror2 expression levels were seen in 63% of hepatocellular patients in comparison 
to adjacent paired normal tissue samples and correlated with a significantly reduced overall 
survival rate (125). Though these results are seemingly inconsistent with previous findings 
regarding Ror2’s tumor-promoting capacity, it is important to note that reintroduction of Ror2 
in colorectal cancer cells resulted in a decrease in β-catenin-dependent signaling,  
constitutive activation of which serves as the driving force in colorectal cancer (129). These 
results suggest Ror2’s identity as a tumor promoter or suppressor is dependent upon the 
context of expression and the state of Wnt/β-catenin-dependent signaling within the tumor. 
A precedent for this scenario may be observed in several of the Wnt antagonists including 
dickkopf -1 (DKK1) and secreted Frizzled-related proteins 1-3 (SFRP1-3) which have shown 
the ability to serve in both roles of tumor promoter and suppressor in various cancer 
contexts (130,131). 
  
Wnt Signaling 
Wnt signaling is a highly conserved network effecting a diverse set of processes 
within adult tissue homeostasis and embryonic development, including migration, cell/tissue 
polarity, cell proliferation, cytoskeletal arrangement, stem cell renewal, and differentiation 
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(132,133). Considering that Wnt signaling contributes to such a varied array of cellular 
functions it is unsurprising that disruptions in the activity and/or regulation of Wnt signaling 
have been linked to various developmental defects including skeletal diseases (134), 
polycystic kidney disease (135-137), and many forms of cancer (134,138). The large range 
of processes and signaling networks regulated by Wnt signaling can be partially attributed to 
the multitude of ligand/receptor combinations possible between the 19 members of the Wnt 
family, 10 Frizzled (Fzd) receptors, and additional Wnt receptors found in mice and humans. 
In addition the tight regulation of the spatiotemporal expression of these Wnt ligands and 
receptors during development allows for crosstalk between the Wnt signaling pathways. 
Following the original discovery of the Wnt-1 (int-1) ligand, members were originally 
divided into two classes: canonical (β-catenin-dependent) and non-canonical (β-catenin-
independent), according to their ability to transform C57mg mammary epithelial cells and 
activate β-catenin-mediated transcription (139-141). This classification placed Wnt1, 3, 3a, 
and 7a as canonical Wnts, with Wnt2, 4, 5a, 5b, 6, 7b and 11 as non-canonical Wnts. 
However, this classification of Wnt ligands may be artifactual or incomplete since crossover 
between the β-catenin-dependent and independent Wnt signaling has been well 
documented as a result of receptor context. The most extensively used ‘non-canonical’ 
ligand, Wnt5a, has been shown to be able to either stimulate or repress β-catenin 
dependent signaling both in vitro and in vivo depending upon the context of the 
spatiotemporal expression of various Wnt receptors (142-144). Thus future examinations of 
Wnt signaling cascades need to be viewed through cellular and receptor context. 
β-catenin-dependent Wnt signaling 
β-catenin-dependent Wnt signaling is the most well-characterized cascade and is 
triggered by Wnt ligand engaging Fzd and low density lipoprotein receptor-related protein 5 
or 6 (LRP5/6) heterodimers. This signal is transduced through activation of dishevelled 
(DVL) which inhibits phosphorylation of β-catenin within the destruction complex consisting 
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of casein kinase 1α (CK1α), glycogen synthase kinase-β (GSK3-β), adenomatous polyposis 
coli (APC), and Axin. The resulting accumulating stabilized Β-catenin is translocated into the 
nucleus, binding to transcription factors including T cell factor (TCF) and lymphoid enhancer-
binding factor (LEF), regulating expression of target genes such as the negative feedback 
regulator Axin2. However, under conditions where no Wnt ligand is bound, β-catenin is 
sequentially phosphorylated by CK1α and GSK3-β within the destruction complex. β-catenin 
is then polyubiquitinated following recruitment of the β-TrCP-containing E3 ubiquitin ligase, 
marking it for proteasomal degradation (134,145) (Figure 1.4A). 
β-catenin-independent Wnt signaling 
β-catenin-independent Wnt signaling does not utilize the coreceptor LRP5/6 or β-
catenin and is mediated solely through Fzd or other non-canonical Wnt receptors. The first 
of the β-catenin-independent pathways is referred to as the planar cell polarity pathway 
(PCP). Wnt/PCP cascade is initiated through Fzd receptor engagement of the Wnt ligand 
resulting in activation of DVL, then Disheveled-Associated Activator of Morphogenesis 1 
(DAAM1) and/or the GTPases Rac1 and RhoA. The signal is further transduced with the 
activation of the kinases c-Jun N-terminal kinase (JNK) and Rho kinase 1 (ROCK1), 
resulting in changes in cell polarity, movement, and inhibition of β-catenin-dependent 
signaling (Figure 1.4B). 
The second of the β-catenin-independent pathways is the Wnt/Ca2+ pathway which, 
akin to the Wnt/PCP pathway, is mediated solely through the Fzd receptor. Upon 
engagement with the Wnt ligand the Fzd receptor leads to the activation of DVL. The 
cascade continues through activation of phospholipase C (PLC) resulting in a release of 
intracellular Ca2+ and activation of calcineurin, calcium-calmodulin kinase II (CamKII) and 
protein kinase C (PKC). Activated calcineurin rapidly dephosphorylates NFAT resulting in its 
translocation into the nucleus to mediate transcription of target genes (Figure 1.4C). 
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Wnt antagonists 
 An additional level of regulation of these Wnt signaling pathways is through several 
families of secreted proteins referred to as Wnt antagonists. These factors have been 
classified into two broad groups based upon their mechanisms of action. The first class of 
secreted antagonist factors comprised of the SFRPs, Wnt inhibitory factor 1 (WIF-1), and 
Cerberus bind directly to Wnt ligands allowing for inhibition of any the Wnt signaling 
cascades. The SFRP family is comprised of 5 members, SFRP1-5, which were originally 
identified in mammals for their regulatory contribution in embryonic development (146,147). 
All members of the SFRP family consist of two domains, a CRD domain, allowing for binding 
of Wnt and Fzd receptors or Tolloid metalloproteases; and a Netrin domain, which has also 
been shown to participate in binding of Wnts (148-152). Although WIF-1 and Ceberus both 
lack a CRD domain they have been shown to be able to bind Wnts and serve as antagonists 
(153,154). The second class of Wnt antagonists consists of the DKK family, which bind the 
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Wnt coreceptors LRP5/6. The DKK family is comprised of four members, DKK1-4, which are 
characterized by two CRD domains (155,156). DKKs mediate their inhibition of β-catenin-
dependent signaling by binding LRP5/6 and initiate either the internalization or disruption of 
its heterodimer with Fzd (157-159). DKK1-2’s inhibition of LRP5/6 requires the concomitant 
binding of the transmembrane protein Kremen. 
As with the other members, many of these Wnt signaling members are able to serve 
in multiple capacities dependent upon the context of their expression. Although the SFRP 
family has been classified as Wnt antagonists, further research has shown their part to be 
much more complicated as they are capable of inhibiting and enhancing Wnt signaling in a 
context-dependent manner (160). DKK2 is further set apart from its family members 
because it is also capable of acting as LRP agonist (161). 
Wnt signaling in renal development and RCC 
As previously described, Wnt signaling plays an extensive role in development, but 
of particular note for this work, previous studies have highlighted the function of Wnt 
signaling in nephrogenesis. The loss of either Wnt9b or Wnt4 results in hypoplasia within the 
developing kidney, due to their regulation of the epithelial differentiation of metanephric 
mesenchymal progenitor cells (162,163). Wnt11 expression is restricted to the tip of the 
ureteric bud, with its loss causing a mild form of hypoplasia within the kidney (164). 
Expression of both SFRP1 and SFRP2 is present during nephrogenesis in tightly-regulated 
spatiotemporal patterns within the developing mesenchyme, which complement or overlap 
the expression of aforementioned Wnt4 (165-167). SFRP1 binds Wnt4, inhibiting β-catenin-
dependent signaling, resulting in decreased tubular differentiation and bud branching. 
SFRP2 competes with SFRP1 for the binding of Wnt4, allowing a dynamic balance to 
achieve proper differentiation and tubule formation within the kidney (165,166). In addition to 
these secreted factors, several Wnt receptors including Ror2 and Fzd are also expressed in 
the developing mesenchyme of the kidney. 
30 
 
Beside its function in development of the kidney, Wnt signaling also plays a role in 
pathology of RCC. Mutations and misregulation of the β-catenin-dependent signaling 
cascade resulting in tumorigenesis or tumor progression have been observed in multiple 
cancers, the most notable being colorectal carcinoma (138,168). However, mutations in the 
typical players (e.g. APC, Axin, and β-catenin) found in other cancers are absent from RCC. 
Several independent groups have shown epigenetic silencing of Wnt antagonists SFRP1-5, 
DKK1-3, and WIF1 in RCC, providing one possible avenue in which Wnt/β-catenin signaling 
may be constitutively activated in RCC (169-176). In seeming contrast to these findings, 
high expression of SFRP1 & SFRP3 in RCC metastases suggests that low SFRP 
expression may be beneficial for tumorigenesis but that high expression may help spur the 
transition to a more aggressive cancer (177,178). Overexpression of SFRP2 and SFRP3 in 
RCC cells resulted in decreased apoptosis, increased cell invasion, and in-vivo tumor 
growth (178,179). Surprisingly, SFRP2 expression in RCC cells also resulted in increased β-
catenin mediated transcription, measured by TopFlash luciferase reporter (179). These 
findings as a whole lend considerable weight to the importance of Wnt signaling in the 
initiation and progression of RCC. 
 
Significance 
 Although in recent years progress has been made in the care and treatment of RCC 
patients, the need for new targeted therapies for RCC remains. Owing to increased 
understanding of the underlying molecular biology of RCC, many new targets are being 
discovered or rediscovered. The identification of the RTK Ror2 as a novel target for RCC 
provides a needed window for the development of new therapeutics. However, a lack of 
knowledge of what role Ror2 plays as a receptor in Wnt signaling and its function in tumor 
progression of RCC greatly inhibits this goal. This thesis begins to provide the framework of 
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Ror2 signaling within the various Wnt signaling cascades in the context of RCC, providing 
the tools for further characterization in future studies. Furthermore this thesis expands our 
knowledge of the effects of Ror2 expression in RCC on cell migration, angiogenesis, and the 
potential of Ror2 as a prognostic biomarker for RCC.  
  
32 
 
REFERENCES 
 
1. (2013) Cancer Facts and Figures 2013. American Cancer Society, Inc, 64 
2. Eggener, S. E., Yossepowitch, O., Pettus, J. A., Snyder, M. E., Motzer, R. J., and 
Russo, P. (2006) Renal cell carcinoma recurrence after nephrectomy for localized 
disease: predicting survival from time of recurrence. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 24, 3101-3106 
3. Motzer, R. J., and Russo, P. (2000) Systemic therapy for renal cell carcinoma. J. 
Urol. 163, 408-417 
4. Linehan, W. M., Pinto, P. A., Srinivasan, R., Merino, M., Choyke, P., Choyke, L., 
Coleman, J., Toro, J., Glenn, G., Vocke, C., Zbar, B., Schmidt, L. S., Bottaro, D., and 
Neckers, L. (2007) Identification of the genes for kidney cancer: opportunity for 
disease-specific targeted therapeutics. Clinical cancer research : an official journal of 
the American Association for Cancer Research 13, 671s-679s 
5. Choyke, P. L., Glenn, G. M., Walther, M. M., Zbar, B., and Linehan, W. M. (2003) 
Hereditary renal cancers. Radiology 226, 33-46 
6. (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. 
Nature 499, 43-49 
7. Young, A. C., Craven, R. A., Cohen, D., Taylor, C., Booth, C., Harnden, P., Cairns, 
D. A., Astuti, D., Gregory, W., Maher, E. R., Knowles, M. A., Joyce, A., Selby, P. J., 
and Banks, R. E. (2009) Analysis of VHL Gene Alterations and their Relationship to 
Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clinical cancer 
research : an official journal of the American Association for Cancer Research 15, 
7582-7592 
8. Kondo, K., Yao, M., Yoshida, M., Kishida, T., Shuin, T., Miura, T., Moriyama, M., 
Kobayashi, K., Sakai, N., Kaneko, S., Kawakami, S., Baba, M., Nakaigawa, N., 
Nagashima, Y., Nakatani, Y., and Hosaka, M. (2002) Comprehensive mutational 
analysis of the VHL gene in sporadic renal cell carcinoma: relationship to 
clinicopathological parameters. Genes. Chromosomes Cancer 34, 58-68 
9. Shuin, T., Kondo, K., Torigoe, S., Kishida, T., Kubota, Y., Hosaka, M., Nagashima, 
Y., Kitamura, H., Latif, F., Zbar, B., and et al. (1994) Frequent somatic mutations and 
loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary 
human renal cell carcinomas. Cancer Res. 54, 2852-2855 
33 
 
10. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B., and Simon, M. C. (2003) 
Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in 
hypoxic gene regulation. Mol. Cell. Biol. 23, 9361-9374 
11. Covello, K. L., Kehler, J., Yu, H., Gordan, J. D., Arsham, A. M., Hu, C. J., Labosky, 
P. A., Simon, M. C., and Keith, B. (2006) HIF-2alpha regulates Oct-4: effects of 
hypoxia on stem cell function, embryonic development, and tumor growth. Genes 
Dev. 20, 557-570 
12. Raval, R. R., Lau, K. W., Tran, M. G., Sowter, H. M., Mandriota, S. J., Li, J. L., Pugh, 
C. W., Maxwell, P. H., Harris, A. L., and Ratcliffe, P. J. (2005) Contrasting properties 
of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal 
cell carcinoma. Mol. Cell. Biol. 25, 5675-5686 
13. Pause, A., Lee, S., Lonergan, K. M., and Klausner, R. D. (1998) The von Hippel-
Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. 
Proc. Natl. Acad. Sci. U. S. A. 95, 993-998 
14. Schoenfeld, A. R., Parris, T., Eisenberger, A., Davidowitz, E. J., De Leon, M., 
Talasazan, F., Devarajan, P., and Burk, R. D. (2000) The von Hippel-Lindau tumor 
suppressor gene protects cells from UV-mediated apoptosis. Oncogene 19, 5851-
5857 
15. Roe, J. S., and Youn, H. D. (2006) The positive regulation of p53 by the tumor 
suppressor VHL. Cell Cycle 5, 2054-2056 
16. Davidowitz, E. J., Schoenfeld, A. R., and Burk, R. D. (2001) VHL induces renal cell 
differentiation and growth arrest through integration of cell-cell and cell-extracellular 
matrix signaling. Mol. Cell. Biol. 21, 865-874 
17. Hoffman, M. A., Ohh, M., Yang, H., Klco, J. M., Ivan, M., and Kaelin, W. G., Jr. 
(2001) von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve 
the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019-1027 
18. Lieubeau-Teillet, B., Rak, J., Jothy, S., Iliopoulos, O., Kaelin, W., and Kerbel, R. S. 
(1998) von Hippel-Lindau gene-mediated growth suppression and induction of 
differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. 
Cancer Res. 58, 4957-4962 
19. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70 
34 
 
20. Morais, C., Gobe, G., Johnson, D. W., and Healy, H. (2011) The emerging role of 
nuclear factor kappa B in renal cell carcinoma. The international journal of 
biochemistry & cell biology 43, 1537-1549 
21. Pantuck, A. J., An, J., Liu, H., and Rettig, M. B. (2010) NF-kappaB-dependent 
plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau 
inactivation in renal cell carcinomas. Cancer Res. 70, 752-761 
22. Koochekpour, S., Jeffers, M., Wang, P. H., Gong, C., Taylor, G. A., Roessler, L. M., 
Stearman, R., Vasselli, J. R., Stetler-Stevenson, W. G., Kaelin, W. G., Jr., Linehan, 
W. M., Klausner, R. D., Gnarra, J. R., and Vande Woude, G. F. (1999) The von 
Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter 
factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. 
Cell. Biol. 19, 5902-5912 
23. Pal, S., Claffey, K. P., Dvorak, H. F., and Mukhopadhyay, D. (1997) The von Hippel-
Lindau gene product inhibits vascular permeability factor/vascular endothelial growth 
factor expression in renal cell carcinoma by blocking protein kinase C pathways. The 
Journal of biological chemistry 272, 27509-27512 
24. Escudier, B., Koralewski, P., Pluzanska, A., Ravaud, A., Bracarda, S., Szczylik, C., 
Chevreau, C., Filipek, M., Melichar, B., and Moore, N. (2007) A randomized, 
controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs 
placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. Proc 
Amer Society Clinical Oncology Abstr 3 
25. Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., Shan, M., and 
Bukowski, R. M. (2005) Randomized Phase III trial of the Raf kinase and VEGFR 
inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma 
(RCC) Proc Amer Soc Clin Oncol 23, 4510 
26. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, 
O., Oudard, S., Kim, S. T., Baum, C. M., and Figlin, R. A. (2006) Phase III 
randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-
line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). 
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 
24, No. 18S (June 20 Supplement), 2006: LBA3 24, LBA3 
27. Rini, B. I., Halabi, S., Taylor, J., Small, E. J., and Schilsky, R. L. (2004) Cancer and 
Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or 
interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) 
in metastatic renal cell carcinoma. Clin. Cancer Res. 10, 2584-2586 
35 
 
28. Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, 
C. H., Salman, P., Gladkov, O. A., Kavina, A., Zarba, J. J., Chen, M., McCann, L., 
Pandite, L., Roychowdhury, D. F., and Hawkins, R. E. (2010) Pazopanib in locally 
advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. 
J. Clin. Oncol. 28, 1061-1068 
29. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R. A., Kapoor, A., 
Staroslawska, E., O'Toole, T., Park, Y., and Moore, L. (2006) A phase 3, 
randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the 
combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with 
advanced renal cell carcinoma (adv RCC). Journal of Clinical Oncology, 2006 ASCO 
Annual Meeting Proceedings Part I. 24, LBA4 
30. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., 
Grunwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., Urbanowitz, G., Berg, 
W. J., Kay, A., Lebwohl, D., and Ravaud, A. (2008) Efficacy of everolimus in 
advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled 
phase III trial. Lancet 372, 449-456 
31. Kaelin, W. G., Jr. (2007) The von Hippel-Lindau tumor suppressor protein and clear 
cell renal carcinoma. Clin. Cancer Res. 13, 680s-684s 
32. Li, Y., and Ye, D. (2010) Cancer therapy by targeting hypoxia-inducible factor-1. Curr 
Cancer Drug Targets 10, 782-796 
33. Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, 
H. F., Albaek, C., Schroder, H., and Orum, H. (2008) A RNA antagonist of hypoxia-
inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 7, 
3598-3608 
34. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., and Neckers, L. 
M. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible 
factor-1 alpha-degradative pathway. J. Biol. Chem. 277, 29936-29944 
35. Koga, F., Kihara, K., and Neckers, L. (2009) Inhibition of cancer invasion and 
metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer 
Res 29, 797-807 
36. Ronnen, E. A., Kondagunta, G. V., Ishill, N., Sweeney, S. M., Deluca, J. K., 
Schwartz, L., Bacik, J., and Motzer, R. J. (2006) A phase II trial of 17-(Allylamino)-
17-demethoxygeldanamycin in patients with papillary and clear cell renal cell 
carcinoma. Invest. New Drugs 24, 543-546 
36 
 
37. Yeo, E. J., Chun, Y. S., Cho, Y. S., Kim, J., Lee, J. C., Kim, M. S., and Park, J. W. 
(2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. 
Cancer Inst. 95, 516-525 
38. Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., and Powis, G. (2004) 
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of 
hypoxia-inducible factor-1alpha. Mol Cancer Ther 3, 233-244 
39. Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., 
Kirkpatrick, D. L., and Powis, G. (2008) Molecular mechanisms for the activity of PX-
478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 7, 
90-100 
40. Pourgholami, M. H., Cai, Z. Y., Badar, S., Wangoo, K., Poruchynsky, M. S., and 
Morris, D. L. (2010) Potent inhibition of tumoral hypoxia-inducible factor 1alpha by 
albendazole. BMC Cancer 10, 143 
41. Melillo, G. (2007) Targeting hypoxia cell signaling for cancer therapy. Cancer 
Metastasis Rev. 26, 341-352 
42. Kondo, K., Kim, W. Y., Lechpammer, M., and Kaelin, W. G., Jr. (2003) Inhibition of 
HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1, E83 
43. Zimmer, M., Doucette, D., Siddiqui, N., and Iliopoulos, O. (2004) Inhibition of 
hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol 
Cancer Res 2, 89-95 
44. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., and Kaelin, W. G., Jr. (2002) 
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau 
protein. Cancer Cell 1, 237-246 
45. Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., and 
Klausner, R. D. (2002) The contribution of VHL substrate binding and HIF1-alpha to 
the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255 
46. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., 
Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. (1999) 
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-
dependent proteolysis. Nature 399, 271-275 
47. Kong, H. S., Lee, S., Beebe, K., Scroggins, B., Gupta, G., Lee, M. J., Jung, Y. J., 
Trepel, J., and Neckers, L. (2010) Emetine promotes von Hippel-Lindau-independent 
37 
 
degradation of hypoxia-inducible factor-2alpha in clear cell renal carcinoma. Mol. 
Pharmacol. 78, 1072-1078 
48. Zimmer, M., Ebert, B. L., Neil, C., Brenner, K., Papaioannou, I., Melas, A., Tolliday, 
N., Lamb, J., Pantopoulos, K., Golub, T., and Iliopoulos, O. (2008) Small-molecule 
inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen 
sensing. Mol. Cell 32, 838-848 
49. Oosterwijk-Wakka, J. C., Kats-Ugurlu, G., Leenders, W. P., Kiemeney, L. A., Old, L. 
J., Mulders, P. F., and Oosterwijk, E. (2011) Effect of tyrosine kinase inhibitor 
treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-
specific chimeric monoclonal antibody cG250. BJU Int. 107, 118-125 
50. Liu, J., Lin, T. H., Cole, A. G., Wen, R., Zhao, L., Brescia, M. R., Jacob, B., Hussain, 
Z., Appell, K. C., Henderson, I., and Webb, M. L. (2008) Identification and 
characterization of small-molecule inhibitors of Tie2 kinase. FEBS Lett. 582, 785-791 
51. Herbst, R. S., Hong, D., Chap, L., Kurzrock, R., Jackson, E., Silverman, J. M., 
Rasmussen, E., Sun, Y. N., Zhong, D., and Hwang, Y. C. (2009) Safety, 
pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin 
inhibitor, in adult patients with advanced solid tumors. J. Clin. Oncol. 27, 3557 
52. Edelman, G., Bedell, C., Shapiro, G., Pandya, S., Kwak, E., Scheffold, C., Nguyen, 
L., Laird, A., Baselga, J., and Rodon, J. (2010) A phase I dose-escalation study of 
XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with 
advanced malignancies.   
53. Maira, M. (2010) Maira M, Menezes D, Pecchi S, et al. NVP-BKM120, a novel 
inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials, shows significant 
antitumor activity in xenograft and primary tumor models.   
54. Brana, I., LoRusso, P., Baselga, J., Heath, E., Patnaik, A., Gendreau, S., Laird, A., 
and Papadopoulos, K. (2010) A phase I dose-escalation study of the safety, 
pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a 
PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced 
malignancies.   
55. Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., 
Brachmann, S., Chene, P., De Pover, A., Schoemaker, K., Fabbro, D., Gabriel, D., 
Simonen, M., Murphy, L., Finan, P., Sellers, W., and Garcia-Echeverria, C. (2008) 
Identification and characterization of NVP-BEZ235, a new orally available dual 
phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in 
vivo antitumor activity. Mol Cancer Ther 7, 1851-1863 
38 
 
56. Zhu, J., Huang, J. W., Tseng, P. H., Yang, Y. T., Fowble, J., Shiau, C. W., Shaw, Y. 
J., Kulp, S. K., and Chen, C. S. (2004) From the cyclooxygenase-2 inhibitor 
celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 
inhibitors. Cancer Res. 64, 4309-4318 
57. Najafov, A., Sommer, E. M., Axten, J. M., Deyoung, M. P., and Alessi, D. R. (2010) 
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. 
Biochem. J. 433, 357-369 
58. Xue, Q., Hopkins, B., Perruzzi, C., Udayakumar, D., Sherris, D., and Benjamin, L. E. 
(2008) Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that 
reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 
68, 9551-9557 
59. Carayol, N., Vakana, E., Sassano, A., Kaur, S., Goussetis, D. J., Glaser, H., Druker, 
B. J., Donato, N. J., Altman, J. K., Barr, S., and Platanias, L. C. (2010) Critical roles 
for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival 
of BCR-ABL-expressing leukemic cells. Proc. Natl. Acad. Sci. U. S. A. 107, 12469-
12474 
60. Hoang, B., Frost, P., Shi, Y., Belanger, E., Benavides, A., Pezeshkpour, G., Cappia, 
S., Guglielmelli, T., Gera, J., and Lichtenstein, A. (2010) Targeting TORC2 in 
multiple myeloma with a new mTOR kinase inhibitor. Blood 116, 4560-4568 
61. Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., 
Vincent, J. P., Ellston, R., Jones, D., and Sini, P. (2010) AZD8055 is a potent, 
selective, and orally bioavailable ATP-competitive mammalian target of rapamycin 
kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288 
62. Bismar, T. A., Bianco, F. J., Zhang, H., Li, X., Sarkar, F. H., Sakr, W. A., Grignon, D. 
J., and Che, M. (2003) Quantification of G250 mRNA expression in renal epithelial 
neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin 
sections. Pathology (Phila). 35, 513-517 
63. Opavsky, R., Pastorekova, S., Zelnik, V., Gibadulinova, A., Stanbridge, E. J., 
Zavada, J., Kettmann, R., and Pastorek, J. (1996) Human MN/CA9 gene, a novel 
member of the carbonic anhydrase family: structure and exon to protein domain 
relationships. Genomics 33, 480-487 
64. Stillebroer, A. B., Mulders, P. F., Boerman, O. C., Oyen, W. J., and Oosterwijk, E. 
(2010) Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, 
diagnosis, and therapy. Eur. Urol. 58, 75-83 
39 
 
65. Currie, M. J., Gunningham, S. P., Turner, K., Han, C., Scott, P. A., Robinson, B. A., 
Chong, W., Harris, A. L., and Fox, S. B. (2002) Expression of the angiopoietins and 
their receptor Tie2 in human renal clear cell carcinomas; regulation by the von 
Hippel-Lindau gene and hypoxia. J. Pathol. 198, 502-510 
66. Youn, S. W., Lee, S. W., Lee, J., Jeong, H. K., Suh, J. W., Yoon, C. H., Kang, H. J., 
Kim, H. Z., Koh, G. Y., Oh, B. H., Park, Y. B., and Kim, H. S. (2011) COMP-Ang1 
stimulates HIF-1{alpha}-mediated SDF-1 overexpression and recovers ischemic 
injury through BM-derived progenitor cell recruitment. Blood  
67. Rankin, E. B., Tomaszewski, J. E., and Haase, V. H. (2006) Renal cyst development 
in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. 
Cancer Res. 66, 2576-2583 
68. Kleymenova, E., Everitt, J. I., Pluta, L., Portis, M., Gnarra, J. R., and Walker, C. L. 
(2004) Susceptibility to vascular neoplasms but no increased susceptibility to renal 
carcinogenesis in Vhl knockout mice. Carcinogenesis 25, 309-315 
69. Haase, V. H., Glickman, J. N., Socolovsky, M., and Jaenisch, R. (2001) Vascular 
tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. 
Proc. Natl. Acad. Sci. U. S. A. 98, 1583-1588 
70. Alayev, A., and Holz, M. K. (2013) mTOR signaling for biological control and cancer. 
J. Cell. Physiol. 228, 1658-1664 
71. Guertin, D. A., and Sabatini, D. M. (2007) Defining the role of mTOR in cancer. 
Cancer Cell 12, 9-22 
72. Klein, S., and Levitzki, A. (2009) Targeting the EGFR and the PKB pathway in 
cancer. Curr. Opin. Cell Biol. 21, 185-193 
73. Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., and 
Ferrara, N. (1998) Vascular endothelial growth factor regulates endothelial cell 
survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. 
Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336-30343 
74. Sourbier, C., Lindner, V., Lang, H., Agouni, A., Schordan, E., Danilin, S., Rothhut, S., 
Jacqmin, D., Helwig, J. J., and Massfelder, T. (2006) The phosphoinositide 3-
kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer 
Res. 66, 5130-5142 
40 
 
75. Porta, C., and Figlin, R. A. (2009) Phosphatidylinositol-3-kinase/Akt signaling 
pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-
kinase/Akt inhibitors. J. Urol. 182, 2569-2577 
76. O'Reilly, K. E., Rojo, F., She, Q. B., Solit, D., Mills, G. B., Smith, D., Lane, H., 
Hofmann, F., Hicklin, D. J., Ludwig, D. L., Baselga, J., and Rosen, N. (2006) mTOR 
inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. 
Cancer Res. 66, 1500-1508 
77. Wan, X., Harkavy, B., Shen, N., Grohar, P., and Helman, L. J. (2007) Rapamycin 
induces feedback activation of Akt signaling through an IGF-1R-dependent 
mechanism. Oncogene 26, 1932-1940 
78. Dowling, R. J., Topisirovic, I., Fonseca, B. D., and Sonenberg, N. (2010) Dissecting 
the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta 1804, 433-
439 
79. Schor-Bardach, R., Alsop, D. C., Pedrosa, I., Solazzo, S. A., Wang, X., Marquis, R. 
P., Atkins, M. B., Regan, M., Signoretti, S., Lenkinski, R. E., and Goldberg, S. N. 
(2009) Does arterial spin-labeling MR imaging-measured tumor perfusion correlate 
with renal cell cancer response to antiangiogenic therapy in a mouse model? 
Radiology 251, 731-742 
80. Rini, B. I., and Atkins, M. B. (2009) Resistance to targeted therapy in renal-cell 
carcinoma. Lancet Oncol 10, 992-1000 
81. Burkitt, K., Chun, S. Y., Dang, D. T., and Dang, L. H. (2009) Targeting both HIF-1 
and HIF-2 in human colon cancer cells improves tumor response to sunitinib 
treatment. Mol Cancer Ther  
82. Wright, T. M., and Rathmell, W. K. (2010) Identification of Ror2 as a hypoxia-
inducible factor target in von Hippel-Lindau-associated renal cell carcinoma. J. Biol. 
Chem. 285, 12916-12924 
83. Wright, T. M., Brannon, A. R., Gordan, J. D., Mikels, A. J., Mitchell, C., Chen, S., 
Espinosa, I., van de Rijn, M., Pruthi, R., Wallen, E., Edwards, L., Nusse, R., and 
Rathmell, W. K. (2009) Ror2, a developmentally regulated kinase, promotes tumor 
growth potential in renal cell carcinoma. Oncogene 28, 2513-2523 
84. Masiakowski, P., and Carroll, R. D. (1992) A novel family of cell surface receptors 
with tyrosine kinase-like domain. J. Biol. Chem. 267, 26181-26190 
41 
 
85. Mikels, A., Minami, Y., and Nusse, R. (2009) Ror2 receptor requires tyrosine kinase 
activity to mediate Wnt5A signaling. J. Biol. Chem. 284, 30167-30176 
86. Akbarzadeh, S., Wheldon, L. M., Sweet, S. M., Talma, S., Mardakheh, F. K., and 
Heath, J. K. (2008) The deleted in brachydactyly B domain of ROR2 is required for 
receptor activation by recruitment of Src. PLoS One 3, e1873 
87. Kani, S., Oishi, I., Yamamoto, H., Yoda, A., Suzuki, H., Nomachi, A., Iozumi, K., 
Nishita, M., Kikuchi, A., Takumi, T., and Minami, Y. (2004) The receptor tyrosine 
kinase Ror2 associates with and is activated by casein kinase Iepsilon. J. Biol. 
Chem. 279, 50102-50109 
88. Nishita, M., Yoo, S. K., Nomachi, A., Kani, S., Sougawa, N., Ohta, Y., Takada, S., 
Kikuchi, A., and Minami, Y. (2006) Filopodia formation mediated by receptor tyrosine 
kinase Ror2 is required for Wnt5a-induced cell migration. J. Cell Biol. 175, 555-562 
89. Lai, S. S., Xue, B., Yang, Y., Zhao, L., Chu, C. S., Hao, J. Y., and Wen, C. J. (2012) 
Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE. 
Cancer Genet 205, 552-562 
90. McKay, S. E., Hislop, J., Scott, D., Bulloch, A. G., Kaczmarek, L. K., Carew, T. J., 
and Sossin, W. S. (2001) Aplysia ror forms clusters on the surface of identified 
neuroendocrine cells. Mol. Cell. Neurosci. 17, 821-841 
91. Wilson, C., Goberdhan, D. C., and Steller, H. (1993) Dror, a potential neurotrophic 
receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of Trk-
related receptor tyrosine kinases. Proc. Natl. Acad. Sci. U. S. A. 90, 7109-7113 
92. Hikasa, H., Shibata, M., Hiratani, I., and Taira, M. (2002) The Xenopus receptor 
tyrosine kinase Xror2 modulates morphogenetic movements of the axial mesoderm 
and neuroectoderm via Wnt signaling. Development 129, 5227-5239 
93. Oishi, I., Takeuchi, S., Hashimoto, R., Nagabukuro, A., Ueda, T., Liu, Z. J., Hatta, T., 
Akira, S., Matsuda, Y., Yamamura, H., Otani, H., and Minami, Y. (1999) Spatio-
temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during 
mouse development: implications in development and function of the nervous 
system. Genes Cells 4, 41-56 
94. Forrester, W. C., Dell, M., Perens, E., and Garriga, G. (1999) A C. elegans Ror 
receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature 
400, 881-885 
42 
 
95. Zinovyeva, A. Y., Yamamoto, Y., Sawa, H., and Forrester, W. C. (2008) Complex 
network of Wnt signaling regulates neuronal migrations during Caenorhabditis 
elegans development. Genetics 179, 1357-1371 
96. Forrester, W. C. (2002) The Ror receptor tyrosine kinase family. Cellular and 
molecular life sciences : CMLS 59, 83-96 
97. Forrester, W. C., Kim, C., and Garriga, G. (2004) The Caenorhabditis elegans Ror 
RTK CAM-1 inhibits EGL-20/Wnt signaling in cell migration. Genetics 168, 1951-
1962 
98. DeChiara, T. M., Kimble, R. B., Poueymirou, W. T., Rojas, J., Masiakowski, P., 
Valenzuela, D. M., and Yancopoulos, G. D. (2000) Ror2, encoding a receptor-like 
tyrosine kinase, is required for cartilage and growth plate development. Nat. Genet. 
24, 271-274 
99. Takeuchi, S., Takeda, K., Oishi, I., Nomi, M., Ikeya, M., Itoh, K., Tamura, S., Ueda, 
T., Hatta, T., Otani, H., Terashima, T., Takada, S., Yamamura, H., Akira, S., and 
Minami, Y. (2000) Mouse Ror2 receptor tyrosine kinase is required for the heart 
development and limb formation. Genes Cells 5, 71-78 
100. Al-Shawi, R., Ashton, S. V., Underwood, C., and Simons, J. P. (2001) Expression of 
the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev. 
Genes Evol. 211, 161-171 
101. Matsuda, T., Nomi, M., Ikeya, M., Kani, S., Oishi, I., Terashima, T., Takada, S., and 
Minami, Y. (2001) Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, 
during mouse development. Mech. Dev. 105, 153-156 
102. Ho, H. Y., Susman, M. W., Bikoff, J. B., Ryu, Y. K., Jonas, A. M., Hu, L., Kuruvilla, 
R., and Greenberg, M. E. (2012) Wnt5a-Ror-Dishevelled signaling constitutes a core 
developmental pathway that controls tissue morphogenesis. Proc. Natl. Acad. Sci. U. 
S. A. 109, 4044-4051 
103. Yamada, M., Udagawa, J., Matsumoto, A., Hashimoto, R., Hatta, T., Nishita, M., 
Minami, Y., and Otani, H. (2010) Ror2 is required for midgut elongation during 
mouse development. Dev. Dyn. 239, 941-953 
104. Stricker, S., Verhey van Wijk, N., Witte, F., Brieske, N., Seidel, K., and Mundlos, S. 
(2006) Cloning and expression pattern of chicken Ror2 and functional 
characterization of truncating mutations in Brachydactyly type B and Robinow 
syndrome. Dev. Dyn. 235, 3456-3465 
43 
 
105. Paganoni, S., and Ferreira, A. (2003) Expression and subcellular localization of Ror 
tyrosine kinase receptors are developmentally regulated in cultured hippocampal 
neurons. J. Neurosci. Res. 73, 429-440 
106. Hatta, K., Chen, Z., Carter, A. L., Leno-Duran, E., Zhang, J., Ruiz-Ruiz, C., Olivares, 
E. G., MacLeod, R. J., and Croy, B. A. (2010) Orphan receptor kinase ROR2 is 
expressed in the mouse uterus. Placenta 31, 327-333 
107. Pacheco, II, and Macleod, R. J. (2008) CaSR stimulates secretion of Wnt5a from 
colonic myofibroblasts to stimulate CDX2 and sucrase-isomaltase using Ror2 on 
intestinal epithelia. Am J Physiol Gastrointest Liver Physiol 295, G748-759 
108. Yamaguchi, T. P., Bradley, A., McMahon, A. P., and Jones, S. (1999) A Wnt5a 
pathway underlies outgrowth of multiple structures in the vertebrate embryo. 
Development 126, 1211-1223 
109. Schwabe, G. C., Tinschert, S., Buschow, C., Meinecke, P., Wolff, G., Gillessen-
Kaesbach, G., Oldridge, M., Wilkie, A. O., Komec, R., and Mundlos, S. (2000) 
Distinct mutations in the receptor tyrosine kinase gene ROR2 cause brachydactyly 
type B. Am J Hum Genet 67, 822-831 
110. van Bokhoven, H., Celli, J., Kayserili, H., van Beusekom, E., Balci, S., Brussel, W., 
Skovby, F., Kerr, B., Percin, E. F., Akarsu, N., and Brunner, H. G. (2000) Mutation of 
the gene encoding the ROR2 tyrosine kinase causes autosomal recessive Robinow 
syndrome. Nat. Genet. 25, 423-426 
111. Afzal, A. R., Rajab, A., Fenske, C. D., Oldridge, M., Elanko, N., Ternes-Pereira, E., 
Tuysuz, B., Murday, V. A., Patton, M. A., Wilkie, A. O., and Jeffery, S. (2000) 
Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by 
mutation of ROR2. Nat. Genet. 25, 419-422 
112. Afzal, A. R., and Jeffery, S. (2003) One gene, two phenotypes: ROR2 mutations in 
autosomal recessive Robinow syndrome and autosomal dominant brachydactyly 
type B. Hum. Mutat. 22, 1-11 
113. Enomoto, M., Hayakawa, S., Itsukushima, S., Ren, D. Y., Matsuo, M., Tamada, K., 
Oneyama, C., Okada, M., Takumi, T., Nishita, M., and Minami, Y. (2009) 
Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. 
Oncogene 28, 3197-3208 
114. Morioka, K., Tanikawa, C., Ochi, K., Daigo, Y., Katagiri, T., Kawano, H., Kawaguchi, 
H., Myoui, A., Yoshikawa, H., Naka, N., Araki, N., Kudawara, I., Ieguchi, M., 
44 
 
Nakamura, K., Nakamura, Y., and Matsuda, K. (2009) Orphan receptor tyrosine 
kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci  
115. O'Connell, M. P., Fiori, J. L., Xu, M., Carter, A. D., Frank, B. P., Camilli, T. C., 
French, A. D., Dissanayake, S. K., Indig, F. E., Bernier, M., Taub, D. D., Hewitt, S. 
M., and Weeraratna, A. T. (2009) The orphan tyrosine kinase receptor, ROR2, 
mediates Wnt5A signaling in metastatic melanoma. Oncogene  
116. Edris, B., Espinosa, I., Muhlenberg, T., Mikels, A., Lee, C. H., Steigen, S. E., Zhu, S., 
Montgomery, K. D., Lazar, A. J., Lev, D., Fletcher, J. A., Beck, A. H., West, R. B., 
Nusse, R., and van de Rijn, M. (2012) ROR2 is a novel prognostic biomarker and a 
potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. 
J. Pathol. 227, 223-233 
117. Kobayashi, M., Shibuya, Y., Takeuchi, J., Murata, M., Suzuki, H., Yokoo, S., Umeda, 
M., Minami, Y., and Komori, T. (2009) Ror2 expression in squamous cell carcinoma 
and epithelial dysplasia of the oral cavity. Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod 107, 398-406 
118. Yamamoto, H., Oue, N., Sato, A., Hasegawa, Y., Matsubara, A., Yasui, W., and 
Kikuchi, A. (2010) Wnt5a signaling is involved in the aggressiveness of prostate 
cancer and expression of metalloproteinase. Oncogene 29, 2036-2046 
119. Kubo, T., Kuroda, Y., Shimizu, H., Kokubu, A., Okada, N., Hosoda, F., Arai, Y., 
Nakamura, Y., Taniguchi, H., Yanagihara, K., Imoto, I., Inazawa, J., Hirohashi, S., 
and Shibata, T. (2009) Resequencing and copy number analysis of the human 
tyrosine kinase gene family in poorly differentiated gastric cancer. Carcinogenesis 
30, 1857-1864 
120. Ohta, H., Aoyagi, K., Fukaya, M., Danjoh, I., Ohta, A., Isohata, N., Saeki, N., 
Taniguchi, H., Sakamoto, H., Shimoda, T., Tani, T., Yoshida, T., and Sasaki, H. 
(2009) Cross talk between hedgehog and epithelial-mesenchymal transition 
pathways in gastric pit cells and in diffuse-type gastric cancers. Br. J. Cancer 100, 
389-398 
121. Lu, B. J., Wang, Y. Q., Wei, X. J., Rong, L. Q., Wei, D., Yan, C. M., Wang, D. J., and 
Sun, J. Y. (2012) Expression of WNT-5a and ROR2 correlates with disease severity 
in osteosarcoma. Mol Med Report 5, 1033-1036 
122. O'Connell, M. P., Fiori, J. L., Xu, M., Carter, A. D., Frank, B. P., Camilli, T. C., 
French, A. D., Dissanayake, S. K., Indig, F. E., Bernier, M., Taub, D. D., Hewitt, S. 
M., and Weeraratna, A. T. (2010) The orphan tyrosine kinase receptor, ROR2, 
mediates Wnt5A signaling in metastatic melanoma. Oncogene 29, 34-44 
45 
 
123. Liu, G., Kukuruzinska, M. A., and Xu, X. (2013) Ror2 may be downregulated in oral 
squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 116, 120 
124. Lara, E., Calvanese, V., Huidobro, C., Fernandez, A. F., Moncada-Pazos, A., Obaya, 
A. J., Aguilera, O., Gonzalez-Sancho, J. M., Sanchez, L., Astudillo, A., Munoz, A., 
Lopez-Otin, C., Esteller, M., and Fraga, M. F. (2010) Epigenetic repression of ROR2 
has a Wnt-mediated, pro-tumourigenic role in colon cancer. Molecular cancer 9, 170 
125. Geng, M., Cao, Y. C., Chen, Y. J., Jiang, H., Bi, L. Q., and Liu, X. H. (2012) Loss of 
Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. 
World J Gastroenterol 18, 1328-1338 
126. Yamagata, K., Li, X., Ikegaki, S., Oneyama, C., Okada, M., Nishita, M., and Minami, 
Y. (2012) Dissection of Wnt5a-Ror2 signaling leading to matrix metalloproteinase 
(MMP-13) expression. The Journal of biological chemistry 287, 1588-1599 
127. Da Forno, P. D., Pringle, J. H., Hutchinson, P., Osborn, J., Huang, Q., Potter, L., 
Hancox, R. A., Fletcher, A., and Saldanha, G. S. (2008) WNT5A expression 
increases during melanoma progression and correlates with outcome. Clinical cancer 
research : an official journal of the American Association for Cancer Research 14, 
5825-5832 
128. Weeraratna, A. T. (2005) A Wnt-er wonderland--the complexity of Wnt signaling in 
melanoma. Cancer metastasis reviews 24, 237-250 
129. Lara, E., Calvanese, V., Huidobro, C., Fernandez, A. F., Moncada-Pazos, A., Obaya, 
A. J., Aguilera, O., Gonzalez-Sancho, J. M., Sanchez, L., Astudillo, A., Munoz, A., 
Lopez-Otin, C., Esteller, M., and Fraga, M. F. (2010) Epigenetic repression of ROR2 
has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol Cancer 9, 170 
130. Saini, S., Majid, S., and Dahiya, R. (2011) The complex roles of Wnt antagonists in 
RCC. Nat Rev Urol 8, 690-699 
131. Menezes, M. E., Devine, D. J., Shevde, L. A., and Samant, R. S. (2012) Dickkopf1: a 
tumor suppressor or metastasis promoter? International journal of cancer. Journal 
international du cancer 130, 1477-1483 
132. Kikuchi, A., and Yamamoto, H. (2008) Tumor formation due to abnormalities in the 
beta-catenin-independent pathway of Wnt signaling. Cancer Sci 99, 202-208 
133. van Amerongen, R., and Nusse, R. (2009) Towards an integrated view of Wnt 
signaling in development. Development 136, 3205-3214 
46 
 
134. Clevers, H., and Nusse, R. (2012) Wnt/beta-catenin signaling and disease. Cell 149, 
1192-1205 
135. Kim, E., Arnould, T., Sellin, L. K., Benzing, T., Fan, M. J., Gruning, W., Sokol, S. Y., 
Drummond, I., and Walz, G. (1999) The polycystic kidney disease 1 gene product 
modulates Wnt signaling. The Journal of biological chemistry 274, 4947-4953 
136. Saadi-Kheddouci, S., Berrebi, D., Romagnolo, B., Cluzeaud, F., Peuchmaur, M., 
Kahn, A., Vandewalle, A., and Perret, C. (2001) Early development of polycystic 
kidney disease in transgenic mice expressing an activated mutant of the beta-catenin 
gene. Oncogene 20, 5972-5981 
137. Qian, C. N., Knol, J., Igarashi, P., Lin, F., Zylstra, U., Teh, B. T., and Williams, B. O. 
(2005) Cystic renal neoplasia following conditional inactivation of apc in mouse renal 
tubular epithelium. The Journal of biological chemistry 280, 3938-3945 
138. Anastas, J. N., and Moon, R. T. (2013) WNT signalling pathways as therapeutic 
targets in cancer. Nature reviews. Cancer 13, 11-26 
139. Du, S. J., Purcell, S. M., Christian, J. L., McGrew, L. L., and Moon, R. T. (1995) 
Identification of distinct classes and functional domains of Wnts through expression 
of wild-type and chimeric proteins in Xenopus embryos. Mol. Cell. Biol. 15, 2625-
2634 
140. Wong, G. T., Gavin, B. J., and McMahon, A. P. (1994) Differential transformation of 
mammary epithelial cells by Wnt genes. Mol. Cell. Biol. 14, 6278-6286 
141. Shimizu, H., Julius, M. A., Giarre, M., Zheng, Z., Brown, A. M., and Kitajewski, J. 
(1997) Transformation by Wnt family proteins correlates with regulation of beta-
catenin. Cell growth & differentiation : the molecular biology journal of the American 
Association for Cancer Research 8, 1349-1358 
142. Mikels, A. J., and Nusse, R. (2006) Purified Wnt5a protein activates or inhibits beta-
catenin-TCF signaling depending on receptor context. PLoS Biol 4, e115 
143. van Amerongen, R., Fuerer, C., Mizutani, M., and Nusse, R. (2012) Wnt5a can both 
activate and repress Wnt/beta-catenin signaling during mouse embryonic 
development. Dev. Biol. 369, 101-114 
144. He, X., Saint-Jeannet, J. P., Wang, Y., Nathans, J., Dawid, I., and Varmus, H. (1997) 
A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 
275, 1652-1654 
47 
 
145. Li, V. S., Ng, S. S., Boersema, P. J., Low, T. Y., Karthaus, W. R., Gerlach, J. P., 
Mohammed, S., Heck, A. J., Maurice, M. M., Mahmoudi, T., and Clevers, H. (2012) 
Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 
complex. Cell 149, 1245-1256 
146. Wang, S., Krinks, M., Lin, K., Luyten, F. P., and Moos, M., Jr. (1997) Frzb, a 
secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell 
88, 757-766 
147. Leyns, L., Bouwmeester, T., Kim, S. H., Piccolo, S., and De Robertis, E. M. (1997) 
Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann 
organizer. Cell 88, 747-756 
148. Rattner, A., Hsieh, J. C., Smallwood, P. M., Gilbert, D. J., Copeland, N. G., Jenkins, 
N. A., and Nathans, J. (1997) A family of secreted proteins contains homology to the 
cysteine-rich ligand-binding domain of frizzled receptors. Proc. Natl. Acad. Sci. U. S. 
A. 94, 2859-2863 
149. Uren, A., Reichsman, F., Anest, V., Taylor, W. G., Muraiso, K., Bottaro, D. P., 
Cumberledge, S., and Rubin, J. S. (2000) Secreted frizzled-related protein-1 binds 
directly to Wingless and is a biphasic modulator of Wnt signaling. The Journal of 
biological chemistry 275, 4374-4382 
150. Lee, H. X., Ambrosio, A. L., Reversade, B., and De Robertis, E. M. (2006) Embryonic 
dorsal-ventral signaling: secreted frizzled-related proteins as inhibitors of tolloid 
proteinases. Cell 124, 147-159 
151. Lopez-Rios, J., Esteve, P., Ruiz, J. M., and Bovolenta, P. (2008) The Netrin-related 
domain of Sfrp1 interacts with Wnt ligands and antagonizes their activity in the 
anterior neural plate. Neural Dev 3, 19 
152. Lin, K., Wang, S., Julius, M. A., Kitajewski, J., Moos, M., Jr., and Luyten, F. P. (1997) 
The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation 
of Wnt signaling. Proc. Natl. Acad. Sci. U. S. A. 94, 11196-11200 
153. Hsieh, J. C., Kodjabachian, L., Rebbert, M. L., Rattner, A., Smallwood, P. M., 
Samos, C. H., Nusse, R., Dawid, I. B., and Nathans, J. (1999) A new secreted 
protein that binds to Wnt proteins and inhibits their activities. Nature 398, 431-436 
154. Piccolo, S., Agius, E., Leyns, L., Bhattacharyya, S., Grunz, H., Bouwmeester, T., and 
De Robertis, E. M. (1999) The head inducer Cerberus is a multifunctional antagonist 
of Nodal, BMP and Wnt signals. Nature 397, 707-710 
48 
 
155. Glinka, A., Wu, W., Delius, H., Monaghan, A. P., Blumenstock, C., and Niehrs, C. 
(1998) Dickkopf-1 is a member of a new family of secreted proteins and functions in 
head induction. Nature 391, 357-362 
156. Krupnik, V. E., Sharp, J. D., Jiang, C., Robison, K., Chickering, T. W., Amaravadi, L., 
Brown, D. E., Guyot, D., Mays, G., Leiby, K., Chang, B., Duong, T., Goodearl, A. D., 
Gearing, D. P., Sokol, S. Y., and McCarthy, S. A. (1999) Functional and structural 
diversity of the human Dickkopf gene family. Gene 238, 301-313 
157. Mao, B., Wu, W., Davidson, G., Marhold, J., Li, M., Mechler, B. M., Delius, H., 
Hoppe, D., Stannek, P., Walter, C., Glinka, A., and Niehrs, C. (2002) Kremen 
proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 
417, 664-667 
158. Wang, K., Zhang, Y., Li, X., Chen, L., Wang, H., Wu, J., Zheng, J., and Wu, D. 
(2008) Characterization of the Kremen-binding site on Dkk1 and elucidation of the 
role of Kremen in Dkk-mediated Wnt antagonism. The Journal of biological chemistry 
283, 23371-23375 
159. Semenov, M. V., Zhang, X., and He, X. (2008) DKK1 antagonizes Wnt signaling 
without promotion of LRP6 internalization and degradation. The Journal of biological 
chemistry 283, 21427-21432 
160. Esteve, P., and Bovolenta, P. (2010) The advantages and disadvantages of sfrp1 
and sfrp2 expression in pathological events. The Tohoku journal of experimental 
medicine 221, 11-17 
161. Wu, W., Glinka, A., Delius, H., and Niehrs, C. (2000) Mutual antagonism between 
dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Current biology : CB 
10, 1611-1614 
162. Carroll, T. J., Park, J. S., Hayashi, S., Majumdar, A., and McMahon, A. P. (2005) 
Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions 
underlying organogenesis of the mammalian urogenital system. Developmental cell 
9, 283-292 
163. Stark, K., Vainio, S., Vassileva, G., and McMahon, A. P. (1994) Epithelial 
transformation of metanephric mesenchyme in the developing kidney regulated by 
Wnt-4. Nature 372, 679-683 
164. Majumdar, A., Vainio, S., Kispert, A., McMahon, J., and McMahon, A. P. (2003) 
Wnt11 and Ret/Gdnf pathways cooperate in regulating ureteric branching during 
metanephric kidney development. Development 130, 3175-3185 
49 
 
165. Lescher, B., Haenig, B., and Kispert, A. (1998) sFRP-2 is a target of the Wnt-4 
signaling pathway in the developing metanephric kidney. Developmental dynamics : 
an official publication of the American Association of Anatomists 213, 440-451 
166. Yoshino, K., Rubin, J. S., Higinbotham, K. G., Uren, A., Anest, V., Plisov, S. Y., and 
Perantoni, A. O. (2001) Secreted Frizzled-related proteins can regulate metanephric 
development. Mech. Dev. 102, 45-55 
167. Vainio, S. J., and Uusitalo, M. S. (2000) A road to kidney tubules via the Wnt 
pathway. Pediatr. Nephrol. 15, 151-156 
168. Moon, R. T., Kohn, A. D., De Ferrari, G. V., and Kaykas, A. (2004) WNT and beta-
catenin signalling: diseases and therapies. Nat Rev Genet 5, 691-701 
169. Gumz, M. L., Zou, H., Kreinest, P. A., Childs, A. C., Belmonte, L. S., LeGrand, S. N., 
Wu, K. J., Luxon, B. A., Sinha, M., Parker, A. S., Sun, L. Z., Ahlquist, D. A., Wood, C. 
G., and Copland, J. A. (2007) Secreted frizzled-related protein 1 loss contributes to 
tumor phenotype of clear cell renal cell carcinoma. Clinical cancer research : an 
official journal of the American Association for Cancer Research 13, 4740-4749 
170. Dahl, E., Wiesmann, F., Woenckhaus, M., Stoehr, R., Wild, P. J., Veeck, J., Knuchel, 
R., Klopocki, E., Sauter, G., Simon, R., Wieland, W. F., Walter, B., Denzinger, S., 
Hartmann, A., and Hammerschmied, C. G. (2007) Frequent loss of SFRP1 
expression in multiple human solid tumours: association with aberrant promoter 
methylation in renal cell carcinoma. Oncogene 26, 5680-5691 
171. Awakura, Y., Nakamura, E., Ito, N., Kamoto, T., and Ogawa, O. (2008) Methylation-
associated silencing of SFRP1 in renal cell carcinoma. Oncol. Rep. 20, 1257-1263 
172. Kawamoto, K., Hirata, H., Kikuno, N., Tanaka, Y., Nakagawa, M., and Dahiya, R. 
(2008) DNA methylation and histone modifications cause silencing of Wnt antagonist 
gene in human renal cell carcinoma cell lines. International journal of cancer. Journal 
international du cancer 123, 535-542 
173. Urakami, S., Shiina, H., Enokida, H., Hirata, H., Kawamoto, K., Kawakami, T., 
Kikuno, N., Tanaka, Y., Majid, S., Nakagawa, M., Igawa, M., and Dahiya, R. (2006) 
Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of 
renal cell carcinoma using tumor and serum DNA. Clinical cancer research : an 
official journal of the American Association for Cancer Research 12, 6989-6997 
174. Kawakami, K., Yamamura, S., Hirata, H., Ueno, K., Saini, S., Majid, S., Tanaka, Y., 
Kawamoto, K., Enokida, H., Nakagawa, M., and Dahiya, R. (2011) Secreted frizzled-
related protein-5 is epigenetically downregulated and functions as a tumor 
50 
 
suppressor in kidney cancer. International journal of cancer. Journal international du 
cancer 128, 541-550 
175. Kawakami, K., Hirata, H., Yamamura, S., Kikuno, N., Saini, S., Majid, S., Tanaka, Y., 
Kawamoto, K., Enokida, H., Nakagawa, M., and Dahiya, R. (2009) Functional 
significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res. 69, 8603-
8610 
176. Hirata, H., Hinoda, Y., Nakajima, K., Kawamoto, K., Kikuno, N., Ueno, K., 
Yamamura, S., Zaman, M. S., Khatri, G., Chen, Y., Saini, S., Majid, S., Deng, G., 
Ishii, N., and Dahiya, R. (2011) Wnt antagonist DKK1 acts as a tumor suppressor 
gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. 
International journal of cancer. Journal international du cancer 128, 1793-1803 
177. Saini, S., Liu, J., Yamamura, S., Majid, S., Kawakami, K., Hirata, H., and Dahiya, R. 
(2009) Functional significance of secreted Frizzled-related protein 1 in metastatic 
renal cell carcinomas. Cancer Res. 69, 6815-6822 
178. Hirata, H., Hinoda, Y., Ueno, K., Majid, S., Saini, S., and Dahiya, R. (2010) Role of 
secreted frizzled-related protein 3 in human renal cell carcinoma. Cancer Res. 70, 
1896-1905 
179. Yamamura, S., Kawakami, K., Hirata, H., Ueno, K., Saini, S., Majid, S., and Dahiya, 
R. (2010) Oncogenic functions of secreted Frizzled-related protein 2 in human renal 
cancer. Mol Cancer Ther 9, 1680-1687 
 
 
 
 
Chapter Two 
 
 
ROR2 EXPRESSION CREATES A POISED STATE OF WNT SIGNALING IN 
RENAL CANCER  
 
Introduction 
Cancer cells usurp many normal signaling processes in the course of transformation 
or acquisition of transformed cell traits. The Wnt signaling pathway is a growth and 
differentiation control pathway central to embryogenesis and cancer (1). The canonical Wnt 
pathway is characterized by secreted Wnt factors, Wnt3a being the most widely studied, 
engaging the receptor complex consisting of low-density lipoprotein receptor-related protein 
(LRP) and a member of the Frizzled (Fzd) family of receptors, halting the basal state of 
ubiquitination and degradation of β-catenin within the destruction complex. As β-catenin 
becomes stabilized it results in the saturation of the destruction complex leading to an 
increase of cytosolic β-catenin and localization to the nucleus (2). Nuclear β-catenin drives 
the transcription of genes involved in promoting cell proliferation, maintenance of a primitive 
state, or induction of differentiation dependent upon cellular context. Wnts can initiate other 
signaling processes, known as non-canonical Wnt signaling pathways, and promote 
migration, establishment of polarity, or programming of morphogenesis (3). In tumors, these 
pathways provide signals for cancer cells to proliferate, acquire stem cell-like properties, and 
secure invasive characteristics as a result of mutations or differential expression of key 
members of these pathways. 
 
(This work is modified from Rasmussen et al Journal of Biological Chemistry, 2013)  
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One of the recently described non-canonical Wnt receptors, the receptor tyrosine 
kinase-like orphan receptor 2 (Ror2) has been implicated in a diverse set of cancers (4-9), 
including renal cell carcinoma (RCC), where aberrant expression occurs as a result of the 
constitutive deregulation of the hypoxia response pathway resulting from loss of the Von 
Hippel-Lindau (VHL) gene (4,10). Ror2 is best known for its role in bone morphogenesis, as 
mutation or loss of this protein in early embryogenesis results in limb foreshortening in 
humans and mouse models (11-13). The expression of Ror2 in mice is restricted to early 
gestation and mesenchymal stem cell niches (14,15). Ror2 is emerging as an intriguing 
mediator of various context-specific Wnt signals in developmental processes as well as 
cancer (16-18). Ror2 has been shown to engage both canonical and non-canonical Wnts, 
and it has been shown to transmit signals related to convergent extension movements, 
planar cell polarity, and proliferation (19,20). Ror2 engagement of Wnt5a has been shown to 
inhibit canonical signaling, however, recent work utilizing primary cell lines showed this 
effect to be Ror2-independent (18,21). The ability of Ror2 to convey situation-appropriate 
signals may contribute to cell-type or situation specific effects, but likely involves availability 
of cofactors, binding partners, or downstream substrates to affect the signal and functional 
outcome.  
Although we have previously shown that Ror2 expression is associated with cellular 
migration and invasion phenotypes in renal carcinoma cells, growth of RCC is also 
facilitated by β-catenin transcription-mediated canonical signals (22). The mediators of this 
signal are thought to be dependent upon the lost expression of the Von Hippel-Lindau tumor 
suppressor (23,24). We therefore decided to explore the signaling pathways related to Ror2 
expression in renal carcinoma and renal-derived cellular systems. Here, we demonstrate 
that human RCC tumors and cell lines show concordance of Ror2 expression with a large 
number of established canonical Wnt pathway targets, suggesting a role of Ror2 in 
mediating β-catenin-dependent signaling. Expression of Ror2 increased the stabilization of 
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β-catenin as well as the transcriptional activity of canonical Wnt target genes, independently 
of exogenously added Wnt3a, and led to the enhancement of the canonical signal when 
exogenous Wnt3a was supplied. Inhibition of the canonical coreceptor LRP6 reduced the 
responsiveness to Wnt3a; however, it did not ablate the Wnt3a-independent increase in β-
catenin. Mutations in the kinase domain of Ror2 abrogated the stabilization of β-catenin and 
Axin2 transcription observed with expression of wild-type protein. These findings 
demonstrate a novel LRP-independent function of Ror2 to maintain an increased signaling 
pool of stable β-catenin in renal cells, while priming cells for additional responsiveness to 
Wnt3a activation of the β-catenin transcriptional pathway. 
 
Results 
Expression of Ror2 in primary human RCC tumors correlates with expression 
of Wnt signaling component gene 
We previously established that Ror2 is expressed in RCC and contributes to three-
dimensional growth, migration, and in vivo tumor growth (4). However, the role of Ror2 as a 
Wnt receptor in RCC remains largely undetermined. Ror2 has been shown to engage both 
canonical and non-canonical Wnt ligands (16-18). We first sought to elucidate the dominant 
pattern of interaction of Ror2 with signaling networks through examination of gene 
expression patterns from 95 human clear cell RCC tumors. An analysis of transcript diversity 
was performed using Agilent microarray data using significance of microarrays (SAM) (25). 
This evaluation yielded 723 genes (Online S. Table 1) that exhibited a significant correlation 
or anti-correlation with Ror2 (False Discovery Rate (FDR) <0.043%). A heat map of these 
genes following an unsupervised clustering exhibited two cluster patterns correlating with 
the level of Ror2 transcript in these tumors (Figure 2.1A). Using DAVID (26,27), a variety of 
significantly enriched gene ontologies (Online S. Table 2) were identified from the genes 
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exhibiting a positive correlation with Ror2. Similar to previous results (4), Ror2 expression 
correlated with many genes playing a role in extracellular matrix (GO:0031012, P-value= 
3.16x10-25) (Figure 2.1B) and skeletal system development (GO:0001501, P-value= 6.11x10-
08) (Figure 2.1C). In addition, enrichment for genes in the Wnt receptor canonical signaling 
pathway (GO:0016055, P-value=2.6x10-4) was also observed (Figure 2.1D). These results 
suggest that the role of Ror2 as a Wnt receptor in RCC tumors may not be limited to non-
canonical Wnt pathways. 
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Expression of Ror2 in RCC cells results in changes of canonical Wnt 
regulators and target genes 
Building on our findings in our human RCC tumors, we examined the effects of Ror2 
expression on gene expression using the Human Wnt Signaling RT2 Profiler PCR Array 
(SABiosciences, Frederick, MD, USA). Three cell lines were used to determine alterations in 
gene expression under basal conditions: the RCC-derived cell line 786-0, which exhibits 
endogenous Ror2 expression; a derived shRNA Ror2 knockdown cell line, 786-0 shRor2; 
and an overexpression cell line, 786-0 TAP-hRor2 (Figure 2.2A). We observed a large 
number of canonical genes displaying concordant expression with Ror2 (Figure 2.2B), 
suggesting a potential association between Ror2 expression and canonical β-catenin 
transcriptional activity independent of Wnt3a stimulation with exogenous ligand. This 
concordant expression pattern with Ror2 was independently verified for targets Fzd1 and 
Jun using independent samples and primer pairs (Figure 2.2C-D). 
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Suppression of Ror2 results in decreased β-catenin mediated transcription in 
RCC cells 
786-0 cells which endogenously express Ror2 were used to more fully determine if 
the aberrant expression of Ror2 in RCC cells contributes to β-catenin-dependent signaling. 
To directly examine canonical Wnt target gene activation in these cells, we first examined 
the mRNA expression of a classic canonical Wnt target gene, Axin2, using quantitative RT-
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PCR. Using two independent shRNAs targeting unique domains of Ror2, we observed a 
significant suppression of Ror2 (Figure 2.3A) and of Axin2 transcription following treatment 
with Wnt3a (Figure 2.3B) in comparison to the control empty vector (786-0 RC3), which also 
exhibited an increase in Ror2 expression with Wnt3a stimulation. These results were 
corroborated using the TOPFlash luciferase-reporter, in which 786-0 pRS (pRetroSuper) 
control showed a significant induction of signal in response to Wnt3a, but no induction was 
observed with shRor2 knockdown cell lines (Figure 2.3C). 
 
Overexpression of Ror2 enhances β-catenin mediated transcription in renal 
and RCC cells 
Prior studies expressing Ror2 in HEK293 cells have focused on concomitant 
treatment of Wnt3a and Wnt5a, but have not elaborated on how Ror2 expression may also 
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potentiate Wnt3a canonical signaling, nor examined the potential for differential signaling 
(18,28). To further examine Ror2 contributions as a mediator of canonical β-catenin 
signaling in RCC, we utilized 786-0 and HEK293T cells expressing a tetracycline-dependent 
fusion protein, Ror2-GFP, or GFP control. Robust expression of Ror2 mRNA was observed 
in 786-0 Ror2-overexpressing cells, relative to control GFP cells following the addition of 
doxycycline, and remained unaltered by treatment with Wnt3a (Figure 2.4A). Upon 
expression of Ror2 there was a significant increase in basal Axin2 mRNA as well as a 
heightened response to Wnt3a treatment (Figure 2.4B). This enhancement of β-catenin 
mediated transcription in the absence of Wnt3a with expression of Ror2, and further 
potentiation was also observed in 786-0 cells transfected with a TOPFlash luciferase-
reporter (Figure 2.4D). 
To validate these findings in an additional renal-derived cell background, we used 
HEK293T cells expressing either GFP or Ror2. Upon the induction of Ror2 in HEK293T 
cells, we again observed significant enhancement of Axin2 transcription and a further 
increase following stimulation with Wnt3a (Figure 2.4F). Likewise, β-catenin-mediated 
transcription measured using the TOPFlash luciferase reporter showed an enhanced 
response to Wnt3a stimulation, although no significant change was detected under basal 
conditions (Figure 2.4H). Inhibition of GSK3-β using LiCl resulted in an additive effect of 
Axin2 transcription with Ror2 expression, suggesting Ror2 effects are mediated through β-
catenin (Figure 2.4C&G). 
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Ror2 expression results in an increased pool of stable β-catenin independent 
of exogenous Wnt stimulation 
Both TCF-luciferase reporters and target gene expression of Axin2 demonstrated 
that Ror2 expression is associated with heightened β-catenin target gene transcription in 
response to Wnt3a stimulation. In addition, expression of Ror2 resulted in enhanced 
transcriptional activity in the absence of exogenous ligand. Therefore, we sought to 
determine if these findings also correlated with the availability of β-catenin for transcriptional 
activation. 
To examine the pool of cytosolic β-catenin available for signaling, protein lysates 
were incubated with concanavalin-A sepharose beads. Immunoblot of 786-0 cell lysates 
revealed an increase of free β-catenin levels (indicated with a *, as compared to total levels) 
upon expression of Ror2, with a further increase following stimulation with Wnt3a CM 
(Figure 2.5A). These results were corroborated in HEK293T cells, demonstrating increased 
stabilized β-catenin upon Ror2 expression that is enhanced with the addition of Wnt3a CM 
in comparison to GFP expressing cells (Figure 2.5B). Quantification of stabilized β-catenin 
relative to total β-catenin is shown below the corresponding bands in each immunoblot. 
To understand the mechanism Ror2 could be using to initiate this poised signaling 
state, we examined upstream pathway components. Dishevelled proteins (DVL2 and DVL3) 
play an important role in canonical Wnt signaling and DVL protein activation via 
phosphorylation has been previously reported as a mediator of Ror2 signaling (21,29-31). 
Expression of Ror2 in 786-0 and HEK293T cells resulted in increased levels of 
phosphorylated DVL2 and DVL3, detected as a shift from the faster migrating band to a 
slower migrating, phosphorylated form, indicative of activation (Figure 2.5A&B). Quantitation 
of pDVL signal relative to total DVL demonstrates increased activation with Ror2 expression 
and in response to Wnt3a. 
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We also examined the receptor LRP6 previously established to be required for Wnt 
ligand-induced β-catenin signaling in mice and Xenopus (32,33). However, while we 
observed expression of LRP6 and its phosphorylation in response to Wnt3a stimulation, no 
effect was observed related to Ror2 expression (Figure 2.5A-C). These data suggest that 
Ror2 expression mediates an LRP6-independent signal resulting in DVL2/3 activation and 
subsequent stabilization of β-catenin. However, Wnt-ligand enhanced signal proceeds via 
LRP6 phosphorylation. 
When we examined suppression of Ror2, 786-0 cells demonstrated no effect on LRP 
activation in response to Wnt3a, consistent with the overexpression studies prior (Figure 
2.5C). However, Ror2 shRNA abrogated the stabilized β-catenin both basally and upon 
Wnt3a CM stimulation (Figure 2.5C). The extent of suppression of Ror2 protein differs 
between the two shRNAs, targeting different sequences in Ror2, with the more potent 
hairpin, shRor2.2, eliciting the most significant reduction in β-catenin stabilization with or 
without Wnt3a. This is demonstrated visually as well as quantitatively. 
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Ror2 dependent stabilization of β-catenin is independent of LRP6 
To further determine what contribution the coreceptor LRP6 has on Ror2 effects in β-
catenin-dependent signaling, we utilized siRNA targeting to deplete cells of LRP6. 
Suppression of the coreceptor LRP6 resulted in the loss of β-catenin stabilization following 
treatment with Wnt3a CM in GFP control cells. Yet, the increased basal β-catenin 
concordant with Ror2 expression remained unaltered (Figure 2.6A). We did observe 
repression of the stimulated signal at the level of Axin2 transcription with siLRP6 in both 
GFP and Ror2 expressing cells, although in HEK293T cells, the basal increased level of 
Axin2 transcript was lost on LRP6 suppression (Figure 2.6C).  
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Dickkopf-1 (DKK1) is an established Wnt antagonist that binds to LRP5/6 leading to 
its internalization from the cell surface. Pretreatment of HEK293T cells with recombinant 
human DKK1 prior to the addition of Wnt3a CM resulted in decreased stabilization of β-
catenin in GFP control cells. However, this addition of DKK1 preceding Wnt3a CM had no 
bearing on the increased β-catenin pool associated with Ror2 expression (Figure 2.6B). 
Quantitative RT-PCR for Axin2 in DKK1-treated cells likewise showed maintenance of 
higher basal levels of transcription than control cells, but with a loss of response to Wnt3a 
stimulation (Figure 2.6D). Together these data suggest that LRP6 cofactor is important 
primarily to transduce the Wnt3a ligand-driven enhanced signal. However, the reduction of 
basal target gene transcript by LRP6 siRNA indicates that LRP6 may retain a minor role in 
mediating this signal. 
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Intact Ror2 kinase domain is required for poised Wnt signaling state 
To determine if Ror2 is directly contributing to these changes in canonical Wnt 
signaling, site-directed mutagenesis was used to disrupt the putative Ror2 kinase domain. 
Ror2-DM contains mutations in two key residues of the catalytic site lysine 507 within the 
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putative ATP binding pocket and aspartate 633 of the DFG (found as DLG in Ror2) motif. 
Despite being expressed at similar levels in 786-0 cells to wild type Ror2, this mutant 
version failed to effectively stabilize β-catenin (Figure 2.7A). A similar pattern of increased 
stable β-catenin levels is seen in HEK293T cells with overexpression of wild-type Ror2, but 
not with expression of the DM mutant (Figure 2.7B). This effect is also shown quantitatively 
below the corresponding immunoblots (Figure 2.7A&B). Quantitative RT-PCR for Axin2 also 
shows a significant decrease with the expression of mutant Ror2 (Ror2-DM) in comparison 
to wild-type Ror2 in both 786-0 (Figure 2.7C) and HEK293T cells (Figure 2.7D). Thus, an 
intact Ror2 kinase domain is necessary for achieving the increased pool of stabilized β-
catenin and for canonical transcript activity independent of Wnt3a stimulation. 
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Wnt/PCP and Wnt/Ca2+ Signaling is independent of Ror2 in RCC cells 
 Ror2 has previously been shown to bind the non-canonical Wnt5a ligand effecting 
and serving as a receptor for non-canonical Wnt signaling pathways; however, these same 
effects have been shown to be Ror2-independent (20,21,29,30,34,35). Because cell context 
seems to influence the role of Ror2 in Wnt signaling, we sought to elucidate if Ror2 also 
serves as a receptor for non-canonical Wnt pathways in RCC cells. First, we looked at 
changes in Wnt/planar cell polarity (PCP) signaling using changes in activity of the GTPases 
RhoA and Rac1 as a functional readout. Although the addition of Wnt5a did result in an 
increase of GTP-bound/active RhoA there was no significant change in either of the stable 
shRor2 knockdowns (Figure 2.8A). Rac1 levels remain unchanged with addition of Wnt5a or 
suppression of Ror2 (Figure 2.8B). Likewise we observed no changes with Wnt5a 
stimulation or Ror2 knockdown in the downstream target of Rac1, c-Jun N-terminal kinase 
(JNK) (Figure 2.8C). To determine if Ror2 serves as receptor for Wnt/Ca2+ pathway, 786-0 
cells were transfected with a nuclear factor associated with T cells (NFAT)-driven luciferase 
reporter which exhibited increases with the addition of Wnt5a that were unaltered with Ror2 
expression. Although these results are not comprehensive they suggest that Wnt/PCP and 
Wnt/ Ca2+ signaling are independent of Ror2 in RCC cells. 
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Discussion 
Renal cell carcinoma has historically been a cancer that challenges conventional 
paradigms. Canonical Wnt signaling disregulation is associated with tumorigenesis and 
progression of RCC, transduced by a previously unknown set of mediating factors (22-
24,36). Furthermore, increased expression of various Wnt ligands including Wnt3a have 
been observed in RCC tumors (36). We sought to identify what role Ror2 played as a Wnt 
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signaling mediator in RCC, as it is capable of engaging a variety of canonical and non-
canonical Wnt ligands (17). In kidney tumors, we show that canonical β-catenin target 
genes, including Axin2, positively correlate with Ror2 expression. A translational validation 
of these results is seen in the multitude of target and canonical component genes showing 
correlated expression with Ror2 in RCC cells and primary human tumors, including pygopus 
1 (PYGO1), secreted Frizzled-related protein 1 (SFRP1), and secreted Frizzled-related 
protein 4 (SFRP4). 
Our data with both kidney-derived cells and kidney cancer cell lines show that Ror2 
expression results in a state of basally enhanced canonical transcriptional signaling due to 
DVL activation and an increased pool of stabilized soluble β-catenin. Stimulation of Ror2-
expressing cells with Wnt3a further enhances the β-catenin pool and transcriptional 
response (Figure 2.9).  
 
The canonical signal cascade requires the canonical coreceptor LRP6 for pathway 
activation in response to Wnt3a, as we observed consistent inhibition with siLRP6 or DKK1 
of β-catenin stabilization as well as Axin2 transcription with the concurrent addition of 
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Wnt3a. Inhibition or knockdown of LRP6, however, showed little effect on the increased pool 
of stabilized β-catenin associated with Ror2 expression in the absence of Wnt3a. This result 
would suggest that the Ror2-dependent tonic signal to stabilize β-catenin and enhance 
transcriptional signals is independent of LRP6. However, siRNA targeting of LRP6, but not 
inhibition with DKK1, inhibited the enhanced basal levels of Axin2 expression seen with 
Ror2, allowing the possibility that Ror2 also involves LRP6 in maintaining this tonic state of 
canonical Wnt signaling. Recent work has demonstrated that β-catenin remains bound in the 
destruction complex and that Wnt stimulation inhibits β-catenin degradation, leading to 
saturation of the complex. As a result, β-catenin accumulates in the cytosolic pool, and then 
is transported into the nucleus and binds to various target genes (2). These data suggest 
that Ror2 can play a role in regulating this available and active pool of β-catenin. The 
increase in measurable soluble β-catenin appears to occur independently of LRP6 co-factor 
recruitment; however, LRP6 may contribute to the transcriptional activation of target genes, 
perhaps via a nuclear influx of β-catenin that is not reflected in the soluble pool in the 
absence of LRP6 or an alternate mechanism. 
Ror2 has been shown to mediate activation of various homologs of DVL, key 
signaling members in multiple Wnt pathways (21,29,30). Our data shows that Ror2 
expression results in an increase in activated (phosphorylated) DVL2/3 in both 786-0 and 
HEK293T cells. These results, combined with the previous findings in the field, suggest DVL 
molecules as possible substrates for the kinase activity of Ror2. However, the potential for 
intermediate substrates or activators of DVL family members cannot be excluded based on 
these findings.  
These findings highlight several relevant points to Wnt signaling and tumor biology. 
First, this model demonstrates that Ror2 activity may be multidimensional. We observed 
substantial changes in canonical signaling with Ror2 expression in RCC and renal-derived 
cell lines in contrast to previous studies reporting Ror2 expression having no effect on β-
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catenin accumulation in response to Wnt3a (30). In addition, we did not observe any 
changes in either the Wnt/PCP or Wnt/Ca2+ signaling pathways dependent on Ror2 
expression with addition of the non-canonical ligand Wnt5a. These expanding cell line 
specific roles of Ror2 can likely be attributed, at least in part, to available coreceptors as well 
as access to Wnt ligands. LRP5/6 is well established as part of the heterodimer responding 
to Wnt ligand binding. Although Ror2 expression results in Wnt3a-independent β-catenin-
dependent stabilization and signaling, the dependence on the expression of LRP6 for Wnt 
induction exhibits the necessity of additional co-receptors for amplifying this signaling 
cascade from the poised state. Fzd2, which was previously reported to cooperate with Ror2 
enhancement of canonical Wnt signaling (16), correlated with Ror2 expression in our set of 
human RCC tumors. Fzd2 represents a candidate cofactor in this regard, highlighting the 
future need for a comprehensive understanding of Ror2 interactions with possible 
coreceptors within the greater cellular context of cancer signaling. 
Based on these observations, it is essential to examine cell signaling effects with an 
emphasis towards differential states of activation. Signals emanating from Wnt receptors 
such as Ror2 may produce partial or incomplete activation of the β-catenin transcriptional 
response repertoire, a feature we have labeled as a poised state of signaling. Engagement 
of the canonical Wnt3a ligand, expressed in RCC tumors, produces a robust enhancement 
that is dependent on the availability of the coreceptor LRP6, and exceeds the Wnt3a 
induced signal in the absence of Ror2. Together, this model system sheds light on the 
specific activity of Ror2 signaling in renal cancer and on the complex nature of this signaling 
pathway which may be critical for dissecting these events in understanding cancer 
progression. Furthermore, this model highlights the potential for a tumor modulator to effect 
moderate pathway activation in a way that primes the pathway for a more intense response 
when a ligand or other source of stimulation becomes available. 
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Ultimately, it is increasingly apparent that Ror2 expression in cancers advances 
signals that provide a variety of advantages for tumor progression. Ror2 serving as a 
mediator of β-catenin dependent signaling in RCC cells and tumors provides a highly 
promising therapeutic target for RCC. 
 
Materials and Methods 
Cell Culture 
786-0 and derivative cell lines, 786-0 RC3 (kindly provided by Dr. Kaelin) (37), 786-0 
pRS, stable monoclonal knockdown 786-0 shRor2.1 and shRor2.2 (4) cells , 786-0 Tap-
hRor2 cells and HEK293T cells were grown in DMEM with 10% FBS, nonessential amino 
acids, L-glutamine, and penicillin/streptomycin. L cells and Wnt3a producing L cells were 
grown in DMEM with 10% FBS. Control and Wnt3a-conditioned media (CM) was collected at 
24 and 48 hours after cells reached confluency. 786-0 cells were transfected with TAP-
hRor2 and selected with 1μg/mL puromycin to generate polyclonal stable lines. HEK293T 
and 786-0 were transduced with lentiviruses carrying the eGFP control, TRE(tight)-eGFP-
pEF1a-rtTA-IRES-Puro or hRor2-eGFP, TRE(tight)-hRor2eGFP-pEF1a-rtTA-IRES-Puro, 
with stable lines generated following selection with 1μg/mL puromycin. 
Plasmids 
The TAP-hRor2 was generated with hRor2 cloned into the pIRESpuro-GLUE 
backbone (38). The control TRE(tight)-eGFP-pEF1a-rtTA-IRES-Puro and TRE-tight-hRor2-
eGFP-eF1a-rtTA-IRES-Puro vectors were generated with eGFP alone or the fusion hRor2-
eGFP, being cloned into a PHAGE6 lentiviral backbone (39). Expression of eGFP or hRor2-
eGFP was visually confirmed 48hr after induction with doxycycline (500ng/mL). Site directed 
mutagenesis using QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies, 
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LaJolla CA) was used to introduce the amino acid substitutions K507M and D633A for 
hRor2-eGFP-DM. 
siRNA 
Stealth siRNA for LRP6 (5 -ACGCAGCAUUGAGCGUGCCAACAAA - 3 and 5 - 
GAUCCCAUGGUUGGGUACAUGU AUU - 3) were pooled and Stealth negative control 
siRNA (Stealth RNAi Negative Control Low GC Duplex) were introduced into cells using 
Lipofectamine RNAiMAX (Invitrogen, Carlsbad CA) according to the manfacturer’s 
instructions and allowed to incubate for 48 hours. 
Quantitative RT-PCR and Human Wnt Signaling RT2 Profiler PCR Array 
Total RNA was extracted from cells using Qiagen RNeasy Mini Kit (Valencia, CA, 
USA). cDNA was made from 500ng of total RNA using Random Primers (Invitrogen, 
Carlsbad CA) and Superscript II RT-PCR reagents (Invitrogen, Carlsbad CA) and analyzed 
using the ABI 7900HT Fast Real-Time PCR System with the following proprietary FAM 
labeled primers: Ror2, Axin2, Fzd1, Jun, 18S, and β-actin (Applied Biosystems, Foster City 
CA). Wnt-related gene expression was examined with the Human Wnt Signaling RT2 Profiler 
PCR Array (SABiosciences, Frederick, MD, USA) using cDNA from 786-0 +TAP-hRor2, 
786-0, and 786-0 shRor2.2 cells with the ABI 7500 Real-Time PCR System. Changes in 
gene expression were calculated following normalization to an internal pool of 5 
housekeeping genes. Note Axin2 was not available in the RT2 Profiler PCR Array. 
Immunoblotting 
Cells were lysed in 10mM Tris, pH 7.4, 100mM NaCl, 1mM EDTA, 1mM EGTA, 1mM 
NaF, 20mM Na4P2O7, 2mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS , 0.5% 
deoxycholate, 1mM PMSF and a protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis IN) and quantitated using Bradford reagent to measure absorbance at 595nm. 
Lysates were separated by SDS-PAGE, transferred to nitrocellulose membranes (GE, 
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Pittsburg, PA) and evaluated using the following antibodies: Ror2 (AF2064, R&D Systems, 
Minneapolis, MN), DVL2 (3216), DVL3 (3218), JNK (9258), pJNK (9255), LRP6 (3395) 
pLRP6 (2568, Cell Signaling Technology, Danvers, MA), Ku80 used as loading control 
(ab1273, AbCam, Cambridge, MA), β-catenin (C2206, Sigma-Aldrich, St. Louis, MO). For all 
immunoblots, following incubation with corresponding secondary antibodies conjugated to 
IR dye 680 or 800, membranes were scanned using the Odyssey IR imager (LI-COR 
Biosciences, Lincoln, NE) with densitometric analysis performed using Odyssey v3.0.21. 
Concanavalin-A Separation of Cytosolic β-catenin 
Cells were incubated for 1 hour with control conditioned media, Wnt3a conditioned 
media (1:2 dil), or DKK1 (400ng/ml, R&D Systems). 50μg of protein lysates from each 
sample as determined by Bradford assay were rotated with 10μl of prepared concanavalin-A 
Sepharose 4b beads (GE, Pittsburg, PA) overnight at 4˚C. Supernatants were removed 
following a brief centrifugation and analyzed by SDS-PAGE. 
Affinity-Precipitation of cellular GTP-RhoA/Rac1 
Active RhoA pulldown experiments were done as described previously (40). Cells 
were lysed in 300µl 50mM Tris, pH 7.4, 10mM MgCl2, 500mM NaCl, 1% Triton X-100, 0.1% 
SDS, 0.5% deozycholate, 1mM PMSF, and 10μg/ml each of aprotinin and leupeptin. 
Lysates were cleared by centrifugation and supernatants were rotated with 20-30µg GST-
RBD conjugated to glutathione–Sepharose beads (GE, Pittsburg, PA). Beads were washed 
with 50mM Tris, pH 7.4, 10mM MgCl2, 150mM NaCl, 1% Triton X-100, 1mM PMSF, and 
10μg/ml each of aprotinin and leupeptin. For active Rac1 pulldown assays, cells were lysed 
in 300µl 50mM Tris, pH 7.4, 10mM MgCl2, 150mM NaCl, 1% Triton X-100, 1mM PMSF, and 
10μg/ml each of aprotinin and leupeptin and rotated with 30-50µg GST-PBD conjugated to 
glutathione–Sepharose beads. Active and total levels of RhoA and Rac1 were analyzed by 
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SDS-PAGE. Densitometry for each scanned immunoblot was performed using ImageJ and 
averaged across duplicate experiments. 
Luciferase Assays 
To determine the activity of the canonical Wnt signaling in the RCC cells, 786-0 and 
HEK293T cells were transfected with TOPFlash and constitutive pHRG-renilla luciferase 
reporters. 24 hours post transfection, cells were seeded in triplicate with media being 
replaced after 8 hours with serum-free media and incubated for 20hr. Post serum starvation, 
cells were treated with control PBS or recombinant human Wnt3a (100ng/ml, R&D systems) 
and incubated for 24hr. Luciferase activity was measured from lysed samples using a 
luminometer and the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). 
Relative luciferase units were calculated by the ratio of TOPFlash luciferase activity to 
internal renilla luciferase activity for each sample. 
NFAT transcriptional induced activity was determined following transfection with the 
pGreenfire-NFAT GFP-Luciferase Reporter (System Biosciences, Mountain View, CA). Cells 
were treated with PBS or recombinant human Wnt5a (100ng/ml) and incubated for 24hr. 
Luciferase activity was measured from lysed samples using a luminometer and the Dual-
Luciferase Reporter Assay System (Promega, Madison, WI). 
Microarray Analysis 
Gene expression for 95 human RCC tumors was downloaded and prepared as 
described previously (41). Collection and analysis of these tumors was approved by the 
institutional biomedical ethics review committee. Significance of Analysis of Microarrays 
(SAM) (http://www-stat.stanford.edu/~tibs/SAM/) was used to determine genes that 
significantly correlated with Ror2 expression among the 95 human RCC tumors with a False 
Discovery Rate (FDR) <0.043% and analyzed using DAVID (http://david.abcc.ncifcrf.gov/) to 
identify significantly enriched gene ontologies. 
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Statistical Analysis 
One-way ANOVA analysis was used to generate p-values in the comparison of each 
experimental condition with the control. A p-value of <0.05 was considered significant and 
<0.001 being highly significant. All error bars shown are the calculated standard deviation 
(SD) or standard error of the mean (SEM) across duplicate or triplicate experiments.  
 
Supplementary material for this article can be found at the JBC Web site, 
http://www.jbc.org 
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Chapter Three 
 
 
ROR2 IS A NOVEL PROGNOSTIC BIOMARKER FOR RENAL CELL 
CARCINOMA  
 
Introduction 
  Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, 
accounting for ~3% of all malignancies. Its incidence and mortality rate continue to climb 
steadily ~2–3% per decade (1). RCC is notoriously difficult to treat as it is radioinsensitive 
and highly unresponsive to traditional chemotherapeutic approaches. Approximately one-
third of new patients present with metastatic RCC, for which the 5-year survival rate remains 
only 5-10% (1,2). As such there is an urgent necessity to identify novel therapeutic targets 
that contribute to RCC tumor progression and can also serve as prognostic biomarkers in 
RCC. 
Receptor tyrosine kinase-like orphan receptor 2 (Ror2) is a recently identified tumor 
promoter. Ror2 was initially found to be expressed in RCC and later was found to be 
overexpressed in a variety of cancers including osteosarcoma, metastatic melanoma, gastric 
cancer, prostate cancer, gastrointestinal stromal tumor (GIST), leiomyosarcoma, and 
squamous cell carcinoma of the head and neck (3-10). The aberrant expression of Ror2 in 
these cancers has been shown to promote cell proliferation, migration, invasion, and 
metastasis, mirroring some of its roles in early development (3,4,6,8,11-13). Prior studies 
have effectively presented Ror2’s potential as a prognostic biomarker, with high Ror2 
expression correlating with Enneking surgical stage and tumor metastasis in osteosarcoma 
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(14), metastatic melanoma (12,15), and poorer clinical outcome in GIST and 
leiomyosarcoma (6). Because earlier work has shown that Ror2 expression is associated 
with cellular migration, invasion, and in-vivo tumor growth in RCC, we sought to expand our 
understanding of Ror2’s tumor promoting role and its potential as a prognostic biomarker in 
RCC (16). As Ror2 signaling has been proven to be highly dependent on cellular context, 
we utilized both RCC cell lines and primary human RCC tumors to uncover additional genes 
correlating with Ror2 expression. 
In accordance with previous research, expression of matrix metalloprotease 2 
(MMP2) is associated with Ror2 expression in RCC cells (13). Ror2 regulation of MMP 
expression has been noted, affecting multiple members (MMP1, MMP2, and MMP13) 
across several cell types, with correlating changes in migration and invasion (3,8,11,13,17). 
The MMP family consists of zinc-dependent enzymes capable of degrading the extracellular 
matrix (ECM), including basement membrane components, resulting in increased cell 
motility. Tumor cells have exploited these features of MMPs to promote migration, invasion 
and metastasis. We examined MMP2 expression in renal cells, which increases with the 
addition of exogenous Wnt3a. This response is attenuated or enhanced with the 
suppression or overexpression of Ror2, respectively. Taking note of MMP2’s role in 
mediating migration as extracellular matrix remodeling protease, we further explored the 
effects of Ror2 expression in migration utilizing a Boyden chamber assay. We observed that 
the introduction of mutations in key areas for activity within the kinase domain of Ror2 
abrogates the increase in MMP2 transcription and cell migration observed with expression 
of wild-type Ror2. 
In addition to the correlation of MMP2 with Ror2 expression in RCC cells and primary 
tumors we identified secreted Frizzled related protein 2 (SFRP2), a known regulator of Wnt 
signaling. We observed that Ror2 suppression and overexpression in RCC cells resulted in 
a correlating reduction or increase of protein levels of SFRP2. Prior work has determined 
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that expression of SFRP2 in RCC cells promotes cell proliferation, in-vivo tumor growth, and 
reduces UV-induced apoptosis (18). Although the role of SFRP2 in Wnt signaling is well 
established, more recent studies have unexpectedly shown SFRP2 to be a potent 
angiogenic factor which is expressed in RCC endothelial cells (19). Upon examination of the 
effects of Ror2 and SFRP2 expression in-vivo we observed an increase in both tumor 
growth and vascularity.  
 Like many cancers, RCC consists of an extremely heterogeneous group of tumors 
represented by the wide variability in metastasis, recurrence and survival in individual 
patients. For this reason, multiple prognostic nomograms have been developed using 
clinical and pathological factors to assist in stratifying patients into different categories of risk 
of recurrence or death. Prognostic nomograms currently in use for RCC fall into one of three 
categories: preoperative, post-operative and metastatic; a clear majority have been 
developed for use in the post-operative sphere (20). The preoperative nomogram put forth 
by Raj et al for non-metastatic RCC patients is used to predict likelihood of recurrence after 
resection using the variables of tumor size, evidence of lymphadenopathy and imaging to 
determine necrosis (21,22). Along with histology the American Joint Committee on Cancer’s 
Tumor Node Metastasis (TNM) algorithm forms the core of post-operative prognostic 
nomograms with varying extensions to include necrosis in the Mayo Clinic’s Stage, Size, 
Grade, and Necrosis (SSIGN) algorithm and performance status in UCLA’s Integrated 
Scoring System (UISS) (20,23,24). The Memorial Sloan-Kettering Cancer Center (MSKCC) 
prognostic nomogram from Motzer et al. incorporates a number of additional features for 
use in metastatic RCC: blood measurements of hemoglobin, serum calcium, and lactate 
dehydrogenase, as well as clinical evaluation of performance status and nephrectomy status 
allowing for stratification into low, intermediate, and high risk groups (25). These nomograms 
provide a framework for clinicians to offer assessments of recurrence and survival for 
patients. 
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Since the advent of microarrays, considerable work has been done using gene 
expression analysis to better understand the underlying heterogeneity of RCC and identify 
new biomarkers for use in current nomograms or as independent predictors of survival. A 
recent study using a set of 120 probes was able distinguish two distinct subtypes, ccA and 
ccB, across multiple gene expression datasets of primary ccRCC tumors, with substantially 
divergent gene expression patterns and survival curves (26). ccA is characterized by genes 
associated with classical ccRCC such as hypoxia, angiogenesis, fatty acid metabolism, and 
organic acid metabolism, whereas ccB tumors expression patterns detail a more aggressive 
panel of genes regulating cell adhesion, extracellular matrix remodeling, cell cycle 
progression, and epithelial-mesenchymal transition (EMT) (26). The more aggressive nature 
of ccB tumors is also reflected in a significantly shorter overall and disease-specific survival 
time in comparison to ccA tumors (26). 
As we saw that Ror2 expression correlated with ccB tumors, we examined the 
potential of Ror2 as an independent prognostic biomarker and found that high Ror2 
expression results in a significant increase in tumor growth and a significant decrease in 
overall survival in RCC. Together, these findings show that Ror2 is a novel prognostic 
biomarker and potential therapeutic target in RCC. 
 
Results 
Determination of Ror2 correlated genes in RCC cells and tumors 
 Prior research identified matrix metalloprotease 2 (MMP2) expression to be Ror2 
dependent in RCC and renal tubular epithelial cells following injury (13,27). We sought to 
build on these results in finding additional genes whose expression in RCC correlated with 
Ror2. We utilized Agilent gene expression microarrays to assess mRNA transcripts from 
786-0 cells infected with an shRNA scramble retrovirus serving as a control and two 
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independent shRor2 knockdown cell lines (786-0 shRor2) in duplicate. To identify the genes 
most significantly correlated with Ror2 (FDR <0.05), significance of microarrays (SAM) (28) 
was utilized to examine gene expression patterns following normalization to an internal 
human reference standard, with relative fold change being calculated in reference to control 
786-0 scramble cells which retain endogenous expression of Ror2. The resulting genes 
were clustered in an unsupervised hierarchal fashion and visualized in a heat map. In 
addition to MMP2, over 1100 probes showed a significant reduction in expression 
correlating with suppression of Ror2. 
An intriguing find among these genes was the Wnt signaling regulator, secreted 
frizzled-related protein 2 (SFRP2) which exhibited a strong correlation with Ror2 expression 
across independent probes (Figure 3.1A). SFRP2 is a member of a family of secreted 
factors capable of binding Wnt ligands, that serve primarily as antagonists of Wnt signaling; 
however, SFRP2 expression in RCC cells has been shown to lead to increased stabilized β-
catenin and downstream transcription through a yet undetermined mechanism. SFRP2 
expression in RCC has also been shown to promote cell proliferation, tumor growth, and 
prevent UV-mediated apoptosis. As these results mirror our previous results, with Ror2 
expression resulting in increased β-catenin signaling independent of Wnt, we used 
quantitative RT-PCR to test SFRP2 expression in 786-0 cells to ensure that these results 
were not artifactual (29). SFRP2 showed a significant reduction along with MMP2 in both 
shRor2 knockdown cell lines in comparison to control 786-0 RC3 cells (Figure 3.1B). 
Having determined that SFRP2 mRNA expression correlated with Ror2 expression in 
RCC cells, we sought to evaluate this relationship in primary tumors. Since SFRP2 has been 
proposed to be either a tumor suppressor or promoter in varying cancers we needed to 
determine its expression in RCC tumors. Also, because SFRP2 is a secreted factor its 
interplay with tumor microenvironment is unaccounted for in-vitro, necessitating we examine 
Ror2 and SFRP2 correlation in primary RCC tumors, more fully taking into account in-vivo 
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signaling conditions. Utilizing a panel of 95 primary human RCC tumors, relative gene 
expression was determined using Agilent gene expression microarrays. A heat map of the 
unsupervised clustering of the averaged expression across probes for Ror2, SFRP2, and 
MMP2 exhibited two discrete clusters. Both SFRP2 and MMP2 clustered quite distinctly with 
Ror2 expression, demonstrating that their correlating expression is not an artifact of our in-
vitro system (Figure 3.1C). 
 
Ror2 dependent MMP2 expression is enhanced by Wnt3a stimulation 
 Although previous work has shown MMP2 expression to be Ror2 dependent in RCC 
cells, the effects of Wnt stimulation on this expression have not yet been established (13). 
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Ror2 expression in RCC cells results in a potentiation of β-catenin-dependent signaling; 
accordingly, we utilized 786-0 cells which exhibit endogenous Ror2 expression to assess 
the role of Wnt3a activation of MMP2 in RCC cells (29). Quantitative RT-PCR for MMP2 
showed a significant response to Wnt3a stimulation in control 786-0 RC3 cells, this 
response being attenuated in both shRor2 knockdowns (Figure 3.2A). Paralleling previous 
findings with Axin2, overexpression of Ror2 in HEK293T cells resulted in an increase in 
basal levels of MMP2 that were further enhanced with the addition of Wnt3a (29) (Figure 
3.2B). 
 
Migration in RCC cells is enhanced by Ror2 expression 
Expression of Ror2 has been shown to mediate expression of several MMPs and cell 
migratory/invasive phenotypes in a multitude of cancers including RCC (3,8,11,13,17). To 
further clarify the contribution of Ror2 to cell migration in RCC we utilized a Boyden chamber 
assay, allowing us to observe single cell motility as cells migrated across the membrane in 
response to extracellular signaling cues. Both 786-0 shRor2 knockdown cell lines exhibited 
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reduced rates of cell migration in comparison to 786-0 RC3 cells, in agreement with previous 
research using a scratch wound healing assay (13) (Figure 3.3A). We also examined the 
effects of overexpression of Ror2 in HEK293T cells, where we observed a mirrored increase 
in migration in Ror2 expressing cells relative to GFP control (Figure 3.3B). 
 
Intact Ror2 kinase domain is required for MMP2 expression and migration in 
RCC cells 
 To further determine if Ror2’s contribution to the migratory phenotype in RCC cells 
was dependent upon signaling capacity or solely upon expression, we used 786-0 cells 
which overexpressed either wild-type Ror2 or mutant Ror2-DM generated using site-directed 
mutagenesis. The Ror2-DM kinase domain was mutated in two key regions known to be 
critical for RTK signaling: the ATP binding pocket and the DFG (found as DLG in Ror2) loop 
heretofore described (29). We have previously shown that these mutations in Ror2 result in 
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loss of the enhancement of β-catenin stabilization and induction of downstream Axin2 
transcription in RCC cells (29). Quantitative RT-PCR for Ror2 shows that Ror2 and Ror-DM 
were expressed at comparable levels in 786-0 cells, but expression of Ror2-DM failed to 
increase basal expression of MMP2 (Figure 3.4A). We examined the migratory potential of 
these same cells in a Boyden chamber assay under normal culture conditions and found 
that 786-0 cells expressing Ror2-DM exhibited a corresponding loss in migration compared 
with 786-0 Ror2 cells (Figure 3.4B). 
 
SFRP2 expression is Ror2 dependent in RCC cells 
 In addition to MMP2 we have here shown the novel correlation between the Wnt 
antagonist SFRP2 and Ror2 expression in both RCC cells and primary tumors. To further 
validate this connection between SFRP2 and Ror2 we gauged expression of protein levels 
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by immunoblot in RCC- and renal-derived cells. Suppression of Ror2 in 786-0 cells showed 
a corresponding decrease in SFRP2 in both shRor2 knockdowns targeting separate 
domains of Ror2 (Figure 3.5A). Likewise, overexpression of Ror2 following induction with 
doxycycline in both 786-0 and HEK293T cells resulted in an increase in SFRP2 expression 
(Figure 3.5B&C). 
 
Expression of Ror2 promotes in vivo tumor growth & vascularity 
Based on the expression findings of these microarrays we sought to further 
investigate the relationship of SFRP2 and Ror2 in-vivo, as expression of both have shown to 
be tumor-promoting in RCC cells. Suppression of Ror2 in RCC cells orthotropically injected 
into the kidney resulted in a dramatic reduction of tumor growth in-vivo (13). Moreover, 
overexpression of SFRP2 in RCC cells has been shown to increase cell proliferation in-vitro 
and tumor growth in-vivo (18). To elucidate the effects in-vivo of overexpression of Ror2 in 
RCC cells, we utilized 786-0 cells.Ror2 overexpression in 786-0 cells had no effect on the 
rate of tumor occurrences, however a trend toward increased tumor growth was seen in 
786-0 cells (Figure 3.6A&B). 
To further characterize the effects of Ror2 and SFRP2 expression in-vivo we turned 
to another aspect crucial to increased tumor growth: the supporting vasculature for the 
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tumor. RCC tumors are known to be highly vascularized due to the shift in the VHL/HIF axis 
resulting in increased expression of VEGF. As SFRP2 has also been demonstrated to be an 
important angiogenic factor we stained for the endothelial cell marker CD31 to measure the 
microvessel density in paired tumors from 786-0 xenografts. Overexpression of Ror2 both in 
786-0 cells resulted in a significant rise in microvessel density (Figure 3.6C), suggesting that 
Ror2 and resulting SFRP2 expression contributions to tumor promotion may be partially 
mediated through increases in the supporting vasculature for RCC tumors.  
 
Ror2 expression is higher in ccB tumors 
Prior work by Brannon et al in further elucidating the underlying molecular biology of 
ccRCC led to the uncovering of two distinct molecular subtypes, ccA and ccB (26). A SAM 
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analysis of the gene expression of these two subtypes across 117 tumors showed distinct 
gene expression patterns (Figure 3.7A). As the two subtypes displayed quite divergent 
expression patterns Brannon et al further investigated whether these subtypes correlated 
with changes in survival outcome. Kaplan-Meier plots for cancer-specific survival displayed 
a highly significant survival difference between ccA and ccB with a median survival of 8.6 
versus 2 years (P= 0.0002) and similar differences in overall survival (Figure 3.7B) (26). 
Because Ror2 had prior association with cell migration, tumor growth, and aggressive 
disease paralleling our findings here in RCC (3,8,12,13,15,17), we tested the differential 
expression levels of Ror2 in ccA and ccB tumors within our core dataset of 417 ccRCC 
tumors from The Cancer Genome Atlas (TCGA) (30). Ror2 expression was significantly 
higher in ccB tumors, suggestive of Ror2 playing a tumor-promoting role in RCC (Figure 
3.7C). 
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Ror2 expression predicts poor clinical outcome in patients with RCC 
The TCGA is a National Cancer Institute initiative designed to catalog multiple 
cancers through collaboration, creating a publicly available database of high-quality tumor 
samples with corresponding clinical information, pathology reports, DNA sequencing, DNA 
methylation, copy number, miRNA Expression, mRNA expression, and protein expression. 
The scope and size of the TCGA ccRCC dataset of over 400 tumors with complete clinical 
and molecular information provides sufficient statistical power to more deeply scrutinize the 
underlying molecular biology and provide a more complete picture of ccRCC.  
Using the same core ccRCC TCGA dataset for determining Ror2 expression in ccA 
and ccB subtypes, we classified these tumors into Ror2-High (Z-score>0) and Ror2-Low (Z-
score<0) expression categories dependent upon their normalized Z-score (30). The clinical 
and pathological characteristics of these patients in Table 3.1 showed significant increase in 
mean tumor size (P= 0.048) and a surprising shift away from the expected 2:1 male:female 
ratio (P= 0.047) to ~3:1 ratio with higher Ror2 expression. High Ror2 expressing tumors also 
trended toward being of a higher clinical stage, nuclear grade, and tumor stage (TNM) 
(Figure 3.8A-C). Further examination of these trends is needed to determine if they are truly 
significant.  
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Table 3.1: Summary of clinical characteristics of patients in the TCGA ccRCC dataset 
 TCGA Dataset Ror2-High (Z-score> 0) 
Ror2-Low 
(Z-score <0) 
Sample (n) 417 119 298 
Age at Death 61 (26-90) 61 (26-90) 61 (29-90) 
Gender    
    Male 270 (65%) 90 (76%) 180 (60%) 
    Female 147 (35%) 29 (24%) 118 (40%) 
Prior Tumor    
    Yes 61 (15%) 20 (17%) 41 (14%) 
Clinical Stage    
    Stage I 195 (47%) 49 (41%) 146 (49%) 
    Stage II 40 (10%) 11 (9%) 29 (10%) 
    Stage III 111 (27%) 34 (29%) 77 (26%) 
    Stage IV 71 (17%) 25 (21%) 46 (15%) 
Grade    
    G1 5 (1.2%) 1 (0.8%) 4 (1.3%) 
    G2 175 (42%) 43 (36%) 132 (44%) 
    G3 170 (41%) 43 (36%) 127 (43%) 
    G4 66 (16%) 32 (27%) 34 (11%) 
    GX 1 (0.2%) 0 1 (0.3%) 
Tumor Size (cm) 6.59 7.13 6.38 
Staging (TNM)    
    T1 200 (48%) 51 (43%) 149 (50%) 
    T2 49 (12%) 12 (10%) 37 (12%) 
    T3 162 (39%) 52 (44%) 110 (37%) 
    T4 6 (1.4%) 4 (3%) 2 (0.7%) 
Nodes    
    Node – (N0) 197 (47%) 56 (47%) 141 (47%) 
    Node + (N1) 12 (3%) 4 (3%) 8 (3%) 
    Node unknown (NX) 208 (50%) 59 (50%) 149 (50%) 
Metastasis    
    Mets – (M0) 346 (83%) 95 (80%) 251 (84%) 
    Mets + (M1) 71 (17%) 24 (20%) 47 (16%) 
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ccA and ccB classification within ccRCC has been shown to be an impressive 
prognostic predictor in relation to survival; however, this finding required gene expression 
data across 120 probes (Figure 3.7B). Because higher Ror2 expression correlates with the 
more aggressive ccB subtype and has a prior-mentioned ability to serve as an independent 
biomarker in prostate, melanoma, and osteosarcoma, we sought to determine whether Ror2 
expression could serve as an independent prognostic factor in RCC. This information would 
not only be a valuable contribution to prognostic nomograms currently employed within the 
clinic, but has the potential to develop into a predictive biomarker upon advent of Ror2 
treatments in RCC. 
We first analyzed overall survival for either Ror2-High or Ror2-Low expression from 
the ccRCC TCGA tumors with 95% confidence intervals and the median survival provided in 
Table 3.2. Kaplan-Meier plots showed the Ror2-Low subtype had a highly significant 
survival advantage over patients with high Ror2 expression (P = 0.005) (Figure 3.9A). Next, 
we examined overall survival in patients with no metastases, which likewise showed a 
significant survival difference between Ror2 expression subtypes (P = 0.004) (Figure 3.9B). 
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However, in an analysis of overall survival in ccRCC patients who developed metastases, 
Ror2 expression made no difference in survival time (P = 0.878) (Figure 3.9C). Finally, we 
assessed recurrence-free survival for patients with no metastases; our results exhibited a 
trend toward low Ror2-expressing tumors having a higher survival time (P = 0.292) (Figure 
3.9D), but insufficient tumor samples within in this category prevent a firm determination. 
Even so, these results show Ror2 can serve as a prognostic biomarker in ccRCC, with high 
Ror2 expression correlating with increased tumor severity. 
 
Table 3.2: Median Survival times with 95% confidence intervals 
Survival 
Analysis Subtype 
Median Survival 
(months) 
95% CI for median 
survival (months) 
Overall Survival 
Ror2 Low 90.4 75.5 – N/A 
Ror2 High 62.8 44.1 – 74.1 
Overall Survival 
– No Mets 
Ror2 Low N/A 90.4 – N/A 
Ror2 High 69.2 52.9 – N/A 
Overall Survival 
– Mets 
Ror2 Low 25.2 18.4 – 47.0 
Ror2 High 19.6 11.3 – 51.5 
Recurrence Free 
Survival 
Ror2 Low 77.2 15.0 – N/A 
Ror2 High 19.6 16.2 – N/A 
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Discussion 
Despite advancements in the care of RCC, there remains considerable room for 
improvement through identification of novel therapeutic targets and prognostic factors for 
assessing risk for patients. Ror2 has been shown to play a role in tumor progression in an 
increasing assortment of cancers including RCC through mediation of signaling cascades, 
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resulting in increased cell migration, invasion, and tumor growth. Prior work in RCC showed 
the ECM remodeling protein MMP2 expression to be Ror2-dependent, in congruence with 
our findings here using gene expression microarrays (13). 
We sought to further elucidate the mechanisms of Ror2-dependent regulation of 
MMP2. Although Ror2 has been primarily been identified as receptor for the non-canonical 
Wnt5a ligand, Ror2 expression in the context of RCC has been shown to result in a 
heightened state of canonical β-catenin signaling which is further enhanced by the addition 
of Wnt3a (29). Furthermore, because MMP2 was shown to be induced downstream of the 
Wnt3a/β-catenin signaling cascade, we tested the effects on Wnt3a on MMP2 expression in 
RCC (31,32). Using both shRor2 knockdown and overexpression in 786-0 cells, we found 
that MMP2 expression mirrored the previous findings with the canonical Wnt target gene 
Axin2, suggesting that Ror2’s migratory/invasive phenotype is not limited to Wnt5a/Ror2 
signaling. Although the consistent increased expression of MMPs has been noted with Ror2 
expression in a multitude of cell contexts, here we have uniquely established the need for 
the Ror2 kinase domain in maintaining heightened MMP2 expression. These results suggest 
that Ror2 kinase activity is required to mediate regulation of downstream target genes such 
as MMP2.   
MMP2 has a well-established role in mediating cell migration and invasion through 
degradation of the ECM and basement membrane, allowing for increased cell motility. In 
keeping with previous findings, suppression of Ror2 results in decreased migration in 786-0 
cells. Here we also show that overexpression of Ror2 in HEK293T and 786-0 results in 
increased migration. However, as the Ror2-DM was unable to alter MMP2 expression, 
migration of RCC cells was likewise unaffected, strengthening the argument that Ror2 
kinase activity is required for migration.  
In addition to the Ror2-dependent expression of MMP2, the discovery of the Wnt 
antagonist/agonist SFRP2 regulation by Ror2 is an intriguing discovery. Although SFRP2 is 
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typically thought of as a Wnt signaling antagonist, a recent study showed that SFRP2 
expression in RCC cells enhances β-catenin-dependent signaling (18). As Ror2 expression 
likewise contributes to a poised state of β-catenin-dependent signaling in RCC, these 
findings together raise the possibility that Ror2 effects on B-catenin-dependent signaling are 
partially mediated through SFRP2 (29). RCC is a highly vascularized cancer with anti-
angiogenic therapies forming the backbone of RTK-targeted therapies currently used in the 
clinic. The development of resistance to RTK therapeutics, possibly through upregulation of 
other angiogenic factors, represents a continuing challenge to clinicians in the treatment of 
RCC. SFRP2’s additional function as an angiogenic factor presents a novel target for 
angiogenesis in RCC as previous studies have shown it to be expressed in the vasculature 
of RCC tumors (18,19). Our results which showed significant increases in tumor vascularity 
with overexpression in Ror2 xenografts in-vivo strengthens the proposal of SFRP2 as a 
potential target in RCC. Although overexpression of Ror2 only resulted in a trend towards 
increased tumor growth in xenografts, this trend was validated with the significant increase 
in tumor size observed with high Ror2 expression in primary RCC tumors highlighting Ror2’s 
role in promoting tumor growth and progression. 
A key clinical characteristic of RCC is the 2:1 male:female ratio, but the biology 
driving this difference remains unresolved. Interestingly, we observe a shift between low- 
and high-expressing Ror2 tumors from the expected 2:1 male:female to ~3:1, respectively. 
Indeed, earlier work toward understanding this gender bias showed that men tend to present 
with larger, higher stage, higher grade RCC than women with a poorer overall survival (33). 
High Ror2 expression likewise exhibited a trend towards higher nuclear grade, clinical stage 
and tumor stage in RCC tumors. These results exhibit that Ror2 contribution to a more 
aggressive disease may also help drive differences seen between genders in RCC. Further 
studies are needed to more fully explore the interplay between Ror2 and gender in RCC.  
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Our analysis of Ror2’s potential as a prognostic biomarker for RCC shows that Ror2 
expression is capable of independently predicting overall survival. The inability of Ror2 to 
serve as a distinguishing factor for metastatic RCC is not unsurprising as Ror2 correlates 
with the aggressive ccB subtype of ccRCC. These findings highlight the role of Ror2 in 
promoting a more aggressive RCC and its ability to serve as a prognostic factor in RCC. 
 
Materials and Methods 
Cell Culture 
786-0 and derivative cell lines, 786-0 RC3 and 786-0 WT8 (kindly provided by Dr. W. 
Kaelin, Boston, MA), 786-0 scramble, stable monoclonal knockdown 786-0 shRor2.1 and 
shRor2.2 cells, 786-0 pCDNA6 and hRor2 cells (13), 786-0 GFP, Ror2, and Ror2-DM (29) 
were grown in DMEM with 10% FBS, nonessential amino acids, L-glutamine, and 
penicillin/streptomycin. HEK293T and derivative cell lines, 293T GFP, Ror2, Ror2-DM (29) 
were grown in DMEM with 10% FBS, nonessential amino acids, L-glutamine, and 
penicillin/streptomycin. Expression of all GFP tagged constructs was visually confirmed 24-
48 hours after induction with doxycycline (500ng/mL). 
Quantitative RT-PCR 
Total RNA was extracted from cells using Qiagen RNeasy Mini Kit (Valencia, CA, 
USA). cDNA was made from 500ng of total RNA using Random Primers (Invitrogen, 
Carlsbad CA) and Superscript II RT-PCR reagents (Invitrogen, Carlsbad CA) and analyzed 
using the ABI 7900HT Fast Real-Time PCR System with the following proprietary FAM 
labeled primers: Ror2, MMP2, SFRP2, 18S, and β-actin (Applied Biosystems, Foster City 
CA). 
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Microarray Analysis 
Gene expression for 786-0 scramble, shRor2.1, and shRor2.2 cell lines and  95 
primary human RCC tumors was downloaded and prepared as previously described (34). 
Collection and analysis of these tumors was approved by the institutional biomedical ethics 
review committee. Relative gene expression for 786-0 shRor2.1 and shRor2.2 was 
calculated in reference to 786-0 scramble with significance of microarrays (SAM) used to 
determine the most significant probes positively correlated with Ror2 (FDR < 0.05). 
Unsupervised clustering of the Ror2 correlating probes and the average gene expression of 
all probes for Ror2, SFRP2, and MMP2 across the 95 primary tumors was done using 
Cluster v3.0 and visualized with Java Treeview v.1.1.5r2. 
Immunohistochemistry 
Prepared slides were deparaffinized, rehydrated in graded ethanol, boiled in citrate 
buffer for 30 min for antigen retrieval, and incubated with 1% H202 for 15 min to quench 
endogenous peroxidase activity. Slides were then incubated with the primary rat anti-CD31 
monoclonal antibody at a dilution of 1:50 (ab7388, AbCam, Cambridge, MA) overnight. 
Detection of the primary antibody was performed using Vectastain Elite ABC kit (Rat IgG) kit 
(Vector Laboratories INC., Burlingame, CA) and di-amino benzidine (DAB). All slides were 
counterstained with Hemotoxylin prior to mounting. 
Xenograft Analysis 
500,000 786-0 or 786-0 WT8 cells were injected orthotopically with control pCDNA6 
and hRor2 expressing cells into opposing kidneys in a small cohort of athymic nude (nu/nu) 
female mice and aged 2.5-4 months. The resulting xenograft tumors were harvested and 
measured prior to being formalin-fixed and paraffin-embedded. Slides were prepared from 
serial sections from the prepared tissue blocks by the UNC Animal Histopathology Core. 
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The slides were immunostained for CD31 expression (ab7388, AbCam, Cambridge, MA) as 
detailed above. 
Immunoblotting 
Cells were lysed in 10mM Tris, pH 7.4, 100mM NaCl, 1mM EDTA, 1mM EGTA, 1mM 
NaF, 20mM Na4P2O7, 2mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS , 0.5% 
deoxycholate, 1mM PMSF and a protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis IN) and quantitated using Bradford reagent to measure absorbance at 595nm. 
Lysates were separated by SDS-PAGE, transferred to nitrocellulose membranes (GE, 
Pittsburg, PA) and evaluated using the following antibodies: Ror2 (AF2064, R&D Systems, 
Minneapolis, MN), SFRP2 (sc-13940, Santa Cruz, Santa Cruz, CA), and the loading control 
Ku80 (ab1273, AbCam, Cambridge, MA). For all immunoblots following incubation with 
corresponding secondary antibodies conjugated to IR dye 680 or 800, membranes were 
scanned using the Odyssey IR imager (LI-COR Biosciences, Lincoln, NE) with densitometric 
analysis performed using Odyssey v3.0.21. 
Transwell Migration Assay 
For migration under basal conditions, HEK293T cells were induced with doxycycline 
(500ng/mL) 24 hours prior to be plated at 1x105 cells, 5x104 786-0 cells for shRor2 cell lines, 
and 1x104 786-0 cells expressing Ror2 and Ror2-DM per well respectively in the upper 
chamber of an uncoated 6.5mm 8-μm pore size transwell chamber (Corning, Corning, NY) 
with normal culture media in both top/bottom wells and allowed to migrate for 6 hours or 18 
hours. Following migration, cells were removed from the top of the transwell by gentle 
swabbing. The remaining cells were fixed in 3.7% formaldehyde, washed in PBS, and 
stained with Crystal Violet. The percentage area covered with migrated cells was calculated 
across 7 random low power fields using ImageJ. 
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ccA/ccB Assignment 
All ccA and ccB assignments were made as described previously (26). 
Survival Analysis 
Survival analysis was performed with the Survival library in R v 2.14, using the TCGA 
mRNA sequencing data (30) and associated clinical data compiled July 31, 2012. Ror2 
expression was classified as high for Z-score normalized RPKM (reads per kilobase per 
million) values above 0. Overall survival was calculated as time to death or last follow-up, 
the latter being censored. Overall survival Kaplan Meier graphs were produced and log-rank 
scores calculated for all 417 patients, metastatic negative patients (n=346), and patients 
with metastatic disease (n=71). Recurrence free survival analyses were performed for 
metastatic free patients (n=59). 
Statistical Analysis 
One-way ANOVA analysis was used to generate p-values in the comparison of each 
experimental condition with the control. A p-value of <0.05 was considered significant and 
<0.001, highly significant. All error bars shown are the calculated standard deviation (stdev) 
or standard error of the mean (SEM) across duplicate or triplicate experiments. 
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Chapter Four 
 
 
CONCLUSIONS AND DISCUSSIONS 
 
Overall summary 
Renal cell carcinoma (RCC) remains difficult to treat despite the advent of receptor 
tyrosine kinase (RTK) therapies; only 5-10% of advanced RCC patients survive to 5 years 
(1,2). Though significant research has focused on RTKs as therapeutic targets for various 
cancers, over half of the kinome remains largely uncharacterized, with only a small 
percentage translating into successful utilization in the clinic (Figure 4.1) (3). Prior work by 
Wright et al. identified the RTK receptor tyrosine kinase-like orphan receptor 2 (Ror2), 
expressed in RCC in a VHL/hypoxia inducible factor-2α (HIF-2α)-dependent manner and 
determined that suppression caused loss of cell migration, anchorage-independent growth, 
and tumor growth in-vivo (4,5). However, this work left many questions concerning Ror2’s 
signaling mechanisms and its ability to serve as a prognostic biomarker in RCC. 
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It is crucial in every area of science that one determines if one’s research is novel 
and yet also takes previous works into account in order to build a greater level of 
understanding within the field. The studies herein presented meet these criteria. We have 
demonstrated the unique function of Ror2 in mediating β-catenin-dependent signaling in 
RCC, its expression resulting in a poised state independent of lipoprotein receptor-related 
protein 6 (LRP6). We have shown the need for an intact kinase domain in Ror2 for proper 
enhancement of β-catenin-dependent signaling, matrix metalloprotease 2 (MMP2) 
expression, and cell migration. Furthermore, we have illustrated Ror2’s role in RCC 
tumorigenesis, promoting increased cell migration, tumor vascularity, and tumor growth. 
Finally, we have shown that Ror2 is capable of serving as a prognostic biomarker in RCC, 
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high expression in patients correlating with a more aggressive disease leading to a 
significant decrease in overall survival. 
 
Comparisons to previous work 
Ror2 research is still relatively young in comparison with more established areas. As 
such there is considerable room for new discoveries, but a necessity to analyze one’s 
findings in reference to the fragments scattered within the field. With the majority of the 
literature describing Ror2 as a receptor for the non-canonical Wnt5a ligand, we began our 
investigation by first examining the non-canonical or β-catenin-independent Wnt signaling 
cascades, the planar cell-polarity (PCP) and Ca2+ pathways in RCC cells (6-10). To 
investigate the Wnt/PCP signaling cascade we looked first to changes in the activity of the 
GTPases RhoA, Rac1, and the downstream target of Rac1, c-Jun N-terminal kinase (JNK) 
as functional readouts. Surprisingly we saw no differences between cell lines in reference to 
the expression status of Ror2. This finding was not without precedent as Ho et al. has also 
shown the activation of JNK with Wnt5a to be independent of Ror2 (11). Likewise, we saw 
no changes in Wnt/ Ca2+ signaling with suppression of Ror2 in RCC cells transfected with a 
nuclear factor associated with T cells (NFAT)-driven luciferase reporter. However, these 
results are not a comprehensive analysis of Ror2 interactions with β-catenin-independent 
signaling. There are several possibilities that can account for this discrepancy of our findings 
with previous studies. First, the possibility that our choices of concentration of Wnt5a and 
time window were unable to capture Ror2-dependent differences. Second, it is also possible 
that we missed the pathway mediating this Ror2-dependent migration effect. Further studies 
to determine how these Wnt5a-dependent migration effects are being mediated in RCC cells 
is still needed. 
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Because the primary literature has focused on Ror2/Wnt5a signaling, some intriguing 
aspects of Ror2’s effects on canonical or β-catenin-dependent signaling have been largely 
unnoticed or ignored. Our attention was first to drawn to Ror2’s possible mediation of β-
catenin-dependent signaling after our microarray gene expression analysis in RCC tumors 
identified several enriched gene ontologies from genes with correlating Ror2 expression. 
Previous studies had examined specific members of the Wnt signaling family either through 
RT-PCR or tissue microarrays to determine possible correlations with Ror2. Our approach 
improved on this several ways: first, our use of microarrays versus investigation of 
specifically chosen panels of genes provided a more unbiased method to examine the 
effects of Ror2 expression, thus allowing us to better infer the underlying biology of the 
tumors without assumptions of previous findings; second, our use of a large cohort 
composed of 95 primary tumors increased our statistical power to determine Ror2-
dependent gene expression patterns; finally, our examination of primary human RCC 
tumors, which although more complicated can be more informative than RCC-derived cell 
lines which may have accrued additional characteristics through the subculturing process. 
The use of primary tumors also allowed us to take into account not only the effects of 
autocrine signaling of the tumor cells, but potential paracrine signaling between the tumor 
and the surrounding microenvironment. Unsurprisingly, we found enrichment for genes 
involved with skeletal development and extracellular matrix remodeling in concordance with 
Wright et al findings using a smaller set of RCC tumors (4). However, established Wnt 
signaling components and downstream target genes exhibited a positive correlation with 
Ror2 expression in primary RCC tumors including the canonical feedback target gene Axin2 
and Wnt antagonist/agonist SFRP2. These results were validated using an RT-PCR array 
focused exclusively on Wnt signaling components and target genes in RCC cells with 
suppression and overexpression of Ror2. 
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From these results we examined more closely the function of Ror2 in β-catenin-
dependent signaling in RCC cells. The most intriguing of our finds was that, independent of 
exogenous Wnt3a, Ror2 expression resulted in increased dishevelled 2 and 3 (DVL 2 and 3) 
activation, stabilization of β-catenin, and induction of transcriptional activity measured using 
RT-PCR for Axin2 and a TopFlash luciferase reporter. This Ror2-dependent enhancement 
of the β-catenin signaling cascade resulted in a poised state, leading to further 
enhancement of canonical signaling consequent to the addition of Wnt3a. Prior works by Li 
et al. and Billiard et al. both noted this augmentation of canonical Wnt signaling upon 
expression of Ror2; the augmentation was observed but received no comment in the works 
of Mikels et al., possibly due to its inconsistency among a few experiments (12-15). Our 
findings highlight the need to not rely solely on the standard TopFlash luciferase reporter, as 
the increased sensitivity of RT-PCR more distinctly showed the basal enhancement of Axin2 
transcription with Ror2 expression. In agreement with Li et al. we also observed inhibition of 
β-catenin-dependent transcription with siRNA targeting LRP6, but our results have uniquely 
shown that we do not see suppression of the increased stabilized pool with expression of 
Ror2 (15,16). These findings highlight the necessity of LRP6 in initiating the signaling 
cascade in response to Wnt3a. Li et al. proposed kinase activity was not necessary for the 
enhancement of β-catenin signaling because Ror2 construct containing a K507R mutation 
within the kinase domain didn’t decrease the activity but deletion of the CRD or intracellular 
domains did (15). In our study we utilized a Ror2 double mutant (Ror2-DM) that mutated the 
same K507 residue to a M507 residue along with additional mutation of the gatekeeper 
residue of the DFG (DLG in Ror2) motif D633 to A633, altering two key areas for kinase 
activity as seen in Figure 4.2A. Expression of the Ror2-DM  resulted in an abrogation of the 
stabilization of β-catenin, Axin2, MMP2 transcription and cell migration observed with 
expression of the wild-type Ror2 protein (16). These differences most likely can be attributed 
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to our differing approaches in mutating Ror2, as ours resulted in significant changes in the 
natures of the amino acids and affected both the DFG loop and putative binding pocket. 
 
 In Chapter 3, we presented Ror2’s ability to serve as a tumor promoting factor and a 
prognostic biomarker for RCC. The work presented in these chapters builds on the growing 
literature showcasing Ror2’s promotion of aggressive cancer in osteosarcoma, metastatic 
melanoma, gastrointestinal stromal tumor (GIST), and leiomyosarcoma (LMS) (17-19). A 
consistent feature of Ror2 expression in these cancers is the upregulation of matrix 
metalloproteases (MMPs) and increased cellular migration and invasion (4,20-23). In 
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accordance with previous work in RCC we observed a significant enrichment of extracellular 
remodeling proteases (MMPs and ADAM) and their regulators (TIMP) with Ror2 expression 
(16). In contrast to other cell contexts in which Wnt5a/Ror2 signaling drove expression of 
MMPs, MMP2 expression in renal cells increased with the addition of Wnt3a. Nonetheless, 
that we still saw decreased cell migration in 786-0 to both Wnt3a and Wnt5a with 
suppression of Ror2 suggests that Wnt5a/Ror2 signaling is still contributing to cell migration 
in RCC cells. 
 A truly novel find we identified from the many genes that correlated with Ror2 
expression in RCC primary tumors was the secreted Wnt regulator secreted Frizzled-related 
protein 2 (SFRP2). We validated the Ror2 regulation of SFRP2 expression at both 
transcriptional and translational levels utilizing HEK293T and 786-0 cells. Our choice to 
follow up further on Ror2’s regulation of SFRP2 expression was motivated by two recent 
studies showing novel functions of this protein as a potent angiogenic factor, a tumor growth 
promoting factor, and as a Wnt agonist in RCC cells (24,25). Akin to our results with Ror2, 
SFRP2 induction of β-catenin-dependent signaling was done in the absence of any 
exogenous Wnt. These results suggest that one of the mechanisms Ror2 employs leading 
to increased stabilization of β-catenin may be partially mediated through SFRP2. 
Additionally, our result with Ror2 overexpression leading to increased tumor vascularity in 
xenografts could be due to SFRP2’s function as an angiogenic factor. 
SFRP2 modulation of Wnt signaling centers on its interactions with Wnt ligands or 
Fzd receptors and has primarily been modeled as an antagonist which sequesters Wnts or 
prevents interactions with ligand receptors. However, a recent study showed that SFRP2’s 
agonistic role was mediated by its binding to Fzd receptors (26). SFRP2’s induction of 
angiogenesis was shown to be mediated through the non-canonical Wnt/Ca 2+ pathway with 
the activation of calcineurin and NFAT (25). Upon use of monoclonal antibody targeting 
SFRP2 in MDA-MB-231 cells there was reduction in both nuclear β-catenin and NFAT (27). 
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Effects in both canonical and noncanonical pathways with inhibition of SFRP2 are 
suggestive that it may be independent of its role in binding Wnts and could be mediated 
through binding of Fzd receptors. Additional work is needed to examine SFRP2’s 
contributions to Ror2-mediated Wnt signaling and angiogenesis in RCC cells.  
Prior work by Brannon et al. using gene expression data from multiple data sets of 
primary human tumors resulted in a probe set of 120 genes, capable of discretely separating 
ccRCC into two molecular subtypes, ccA and ccB. Comparison of gene expression patterns 
between these subtypes showed ccA to have features of classical ccRCC, while ccB tumors 
were characterized as more aggressive due to the significant reduction of overall survival 
and expression of genes regulating cell adhesion, extracellular matrix remodeling, cell cycle 
progression, and epithelial-mesenchymal transition (EMT) (28). Given Ror2’s tight link to 
many of these same features in RCC and other cancers, the natural extension was to 
ascertain if Ror2 was differentially expressed between these subtypes. As we predicted, 
Ror2 showed much higher expression in ccB tumors than ccA within TCGA tumors. Yet the 
simple addition of Ror2 into the ccB phenotype is not enough. Our goal was to determine if 
Ror2 could serve as an independent prognostic biomarker in RCC as had been done 
previously in gastrointestinal stromal tumor (GIST) and leiomyosarcoma (LMS) (17). 
The data in the Cancer Genome Atlas (TCGA) for ccRCC is a valuable tool for 
investigating the underlying molecular biology of ccRCC tumors in relation to their known 
clinical features. We examined the effects of Ror2 expression in primary tumors from the 
published TCGA ccRCC dataset, which provided a significantly larger dataset of 417 ccRCC 
tumors with complete clinical features (including tumor size, nuclear grade, clinical stage, 
tumor stage, and survival) for each tumor. From this analysis were able to confirm our trend 
of increased tumor growth in xenografts with significant increase in tumor growth in high 
Ror2-expressing tumors. In agreement with aggressive phenotypes seen in metastatic 
melanoma, osteosarcoma, GIST, and LMS, we saw that higher Ror2 expressing tumors 
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trended to having increased clinical stage, nuclear grade, and tumor stage. A more rigorous 
statistical analysis is needed to determine if these relationships are truly significant. Finally, 
an analysis of overall survival for all patients with and without metastasis showed significant 
decrease with high Ror2 expression. Our findings show that Ror2 can serve as an 
independent prognostic biomarker in RCC and is an attractive therapeutic target in RCC. 
 
Ror2 activities promoting cancer 
 As previously noted, the majority of the field investigating Ror2 has placed it solely 
as a receptor for non-canonical Wnt5a. This paradigm was first established with the 
observed phenotypic overlaps between Wnt5a and Ror2 null mice (29-31). Yet, 
immunoprecipitation experiments of xRor2 found it bound not only Xwnt5a, but Xwnt8 and 
Xwnt11 as well. Additionally in-vitro immunoprecipitation of Ror2 is capable of engaging 
multiple Wnt ligands including Wnt 1, Wnt3, Wnt3a, Wnt5a, and Wnt5b (6,14,32,33). 
However, the ability of Ror2 to bind various Wnts can only infer potential for activity in 
response to each of these ligands. Thus looking at changes in downstream Ror2 signaling in 
response to Wnt ligands is essential to determining the breadth of Ror2’s role as Wnt 
receptor. An examination of Ror2 expression in osteosarcoma cell lines shows this potential 
for differential signaling in response to various Wnt ligands, with Ror2 potentiating β-catenin-
mediated transcription with Wnt1 and inhibiting it in response to Wnt3. (14). In addition both 
Wnt5a and Wnt5b contributed to Ror2-dependent migration in osteosarcoma cells (32). This 
expanded profile of Wnt ligands interacting with Ror2 is also potentially reflected in our RCC 
tumors as both Wnt5b and Wnt4 showed significant correlating expression with Ror2. 
Surprisingly we saw that although Wnt5a did not result in any activation of non-canonical 
signaling in a Ror2-dependent manner, Ror2 expression did lead to an enhancement of 
canonical β-catenin signaling in RCC cells. These results suggest that Ror2 may serve as a 
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dual receptor and thus drive tumor progression. The question becomes, what are the 
mechanisms that regulate and confer Ror2’s differential Wnt signaling? 
 Wnt signaling pathways have shown to be highly dynamic despite the repeated 
usage of core components in multiple pathways. Earlier paradigms had suggested that this 
dynamic nature was only due to the variety of pairings possible between the 19 Wnt ligands 
and the 10 Frizzled (Fzd) receptors, LRP5 and 6, and multiple other receptors. Although this 
is true, a precedent of multi-functionality is seen throughout the members of Wnt signaling. 
Wnt5a is dependent upon receptor context and was shown to be able to activate or inhibit 
canonical Wnt signaling in-vitro and in-vivo (12,34). Sato et al. showed Fzd2 is capable of 
initiating both canonical and non-canonical Wnt planar cell polarity (PCP) signaling 
depending upon its engagement of either Wnt3a or Wnt5a respectively (35). SFRP2 
primarily has been shown to act as an antagonist of Wnt signaling through competitive 
binding of Wnt ligands, but expression of SFRP2 in RCC cells resulted in increased 
canonical Wnt signaling (24). DVL also serves to mediate both canonical and non-canonical 
Wnt pathways. 
 Mechanisms regulating the dual nature of Ror2 may function in several ways. First, 
Ror2 may have differing binding affinities between the Wnt ligands. In both Li et al. and 
Mikels et al. the concomitant addition of Wnt5a with Wnt3a CM with no resulting dilution 
changes resulted in a significant decrease of canonical signaling in Ror2-expressing cells. 
These results suggest that Ror2 may have a greater affinity for Wnt5a than Wnt3a, leading 
to the decreased activity as a result of Wnt3a being unable to bind and/or Wnt5a leading to 
downstream inhibition of β-catenin-dependent signaling. Sato et al. demonstrated that the 
receptor Fzd2 is capable of responding to both Wnt3a and Wnt5a, yet immunoprecipitations 
of Fzd2 with both ligands revealed its slightly increased affinity for Wnt5a (35). The same 
approach could be well used to investigate this possibility of differing affinities of Ror2 and 
Wnt3a. Additionally the use of Shisa, which specifically inhibits Fzd translocation to the 
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membrane by retaining it in the endoplasmic reticulum, would allow a determination of the 
necessity of Fzd coreceptors for Ror2 signaling (36). Second, Ror2 has been shown to 
interact with both Fzd2 and Fzd7 via its CRD domain, with Wnt5a engagement of Ror2-Fzd2 
and Ror2-Fzd7 initiating the Wnt/PCP signaling cascade and enhanced β-catenin-
dependent signaling through Ror2-Fzd2 with Wnt3a (10,15,35). This observed dichotomy of 
Fzd-Ror2 signaling would serve to explain Ror2 correlating canonical Wnt targets in primary 
RCC tumors, as we also see Fzd2 (16). Thus regulation of the dual nature of Ror2 is likely 
accomplished through a combination of the mechanisms of tight regulation of Wnt 
expression, Ror2’s differing affinities for Wnt ligands, and expression of Fzd co-receptors. 
A critical process in solid tumor progression and metastasis is the epithelial to 
mesenchymal transition (EMT), which converts cells from an epithelial, nonmotile 
morphology to become migratory and invasive (37). Wright et al. have shown previously in 
RCC that several key EMT genes, Twist1, Twist2, Snail2 and MMP2, correlated with Ror2 
expression (4). In particular, Snail has been shown to mediate EMT of both epithelial cells 
and carcinomas. Recent work investigating EMT has shown expression of Snail induces 
expression of Ror2 and MPP2 in A431 cells, and suppression of endogenous Snail in 
SaOS-2 resulted in a loss of Ror2 and MMP13 expression (21). Interestingly, this same 
process has been noted in renal fibrosis with induction of Ror2 and MMP2 in damaged 
kidneys. Li et al. found that Ror2 was predominantly expressed in tubular epithelial cells that 
have undergone EMT, as noted by the expression of Snail and other mesenchymal markers 
(38). The importance of these findings is illuminated upon taking into account that the tubule 
cell is thought to be the cell of origin for RCC and that Snail is a HIF target (39,40). Prior 
work with Ror2 by Wright et al. in RCC cells demonstrated its HIF dependence but hypoxia 
independence, showcasing that the reactivation of Ror2 expression in RCC cells may be 
mediated by Snail upon its reactivation by injury or HIF. 
 
121 
 
Is Ror2 a pseudokinase? 
 Receptor tyrosine kinases (RTKs) are generally activated through ligand-induced 
oligomerization, typically homodimerization, resulting in trans-autophosphorylation of the 
kinase domain leading to the recruitment of downstream signaling partners. However, 
among the 58 human RTKs approximately 10% have been predicted to be catalytically 
inactive, termed pseudokinases (41). Despite alterations in several highly conserved 
residues both Ror1 and Ror2 were predicted to be active by Manning et al. (41). Yet, Ror1 
was recently categorized as a pseudokinase by Gentile et al., due to its lack of catalytic 
activity in-vitro and autophosphorylation in cells. A plausible case for Ror2 inclusion as 
pseudokinase is made more clear upon examination of Ror1 and Ror2 kinase domains 
which exhibit a very high degree of amino acid identity (>70%) and share several key 
alterations in regions conserved in most RTKs (Figure 4.3). Among these conserved regions 
in RTK is the glycine-rich loop which associates with phosphate groups of ATP. Both Ror1 
and Ror2 have significant substitutions in the second of the conserved glycine residues, 
most likely distorting the ATP-binding site. The DFG motif is another key conserved region 
playing a key role as metal binding site and in both Ror1 and Ror2 contains a change from 
DFG to DLG. This phenylalanine residue plays an important role in positioning the catalytic 
aspartate residue, yet an examination of the crystal structure for Ror2 kinase domain shows 
the leucine residue replacing the phenylalanine does not spatially interfere with the ATP 
binding pocket region (42). These similarities between Ror1 and Ror2 sequences show the 
possibility of Ror2 being pseudokinase. 
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However, there is opposing evidence to Ror2’s classification as a pseudokinase. The 
original examination by Gentile et al. of Ror1 began by cataloging Ror1 tyrosine 
phosphorylation in 43 cancer cell lines, of which only 3 were positive. Wright et al. in her 
original reporting of Ror2 expression in RCC cells showed that Ror2 did exhibit a basal level 
of phosphorylation which was labeled as autophosphorylation (4). Following this Mikels et al. 
examined Ror2 utilizing an in-vitro kinase activity, showing that immunoprecipitated mRor2 
was capable of transphosphorylating the kinase domain of mRor2 and this capability was 
enhanced by pretreating cells with Wnt5a (13). Additionally, forced dimerization using a 
Ror2-targeted antibody in U2-OS osteosarcoma cells resulted in increased tyrosine 
phosphorylation of endogenous Ror2. Our findings using the Ror2-DM also demonstrate the 
importance of the tyrosine kinase domain in mediating β-catenin-dependent signaling, 
MMP2 expression and cell migration. Taken together these results suggest that Ror2 is an 
active RTK. However without the gold standard of directly showing Ror2’s ability to bind and 
catalytically use ATP we are unable to place Ror2 in either camp of pseudokinase or active 
RTK. 
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Regulation and activation of Ror2 in RCC 
 The dysfunctional signaling by mutated or overexpressed kinases has been 
intimately linked as a potent driving force in cancer (3). The disregulation and constitutive 
activity of many RTKs are the result of mutations within the kinase that enhance or stabilize 
enzymatic activity such as epidermal growth factor receptor (EGFR). Mutations vary in their 
method of activation of kinases, from deletions of extracellular receptors, gain of function 
mutations, or mutations resulting in loss of auto-inhibitory function. EGFR is characterized 
by a series of deletions in the extracellular domain causing constitutive activation. Discovery 
of EGFR expression in non-small cell lung cancer and development of targeted therapeutics 
was thought would result in dramatic responses, however, these EFGR RTK inhibitors have 
been plagued by low response rates and quick turnover to resistance due to additional 
mutations (43,44). A previous study examining mutations of RTK in gastric cancer by Edris 
et al. identified a non-synonymous mutation in 1 of 52 samples resulting in the D644N 
substitution within the kinase domain of Ror2, possibly altering its activity. An analysis of the 
Ror2 mutations observed within the available TCGA datasets suggests that Ror2 mutations 
are, to varying degrees, rare in most  cancers, as noted by a mere  0.2% ccRCC tumors 
(Figure 4.4) (17). 
 Although RTKs are the most commonly mutated genes in cancer, this is by far not 
the only mechanism in which they are activated. Many kinases are upregulated either 
through genetic amplification events or alterations within their regulatory mechanisms. In 
addition to the aforementioned deletion mutants, EFGR is often found to be amplified in 
breast, gastric, ovarian, and non-small cell lung cancer, the resulting overexpression leading 
to increased dimerization and constitutive activation (45). The works of Wright et al. 
concerning Ror2 beautifully laid out the aberrant expression of Ror2 to be dependent upon 
the inactivation of Von-Hippel Lindau protein (pVHL) and hypoxia inducible factor (HIF) 
expression (4,5). These findings placed Ror2 regulation as part of the program resulting 
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from the defining loss of VHL in RCC. As Ror2 expression has now been observed in a 
multitude of cancers beyond RCC, how Ror2 expression, notably missing from most adult 
tissues, becomes reexpressed is an interesting question. The low rate of mutation of Ror2 in 
cancer suggests that its expression in many of these cancers may be mediated through 
either gene amplification or changes in Ror2 regulatory genes such as VHL. 
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Ror2 inhibition in cancer 
 Our findings presented in previous chapters showed Ror2 expression to result in a 
more aggressive RCC, marked by increased cell migration, tumor growth, tumor vascularity, 
and decreased survival, highlighting its great potential as a therapeutic target in RCC. In 
addition Ror2 represents an extremely attractive RTK target due to its very limited 
expression profile within adult tissues and the ever-growing list of cancers in which it is 
expressed. As such the question has become, what is the best avenue for the development 
of Ror2-based therapeutics? 
 Akin to Ror2, Ror1 has been shown to have a tumor-promoting role in a variety of 
cancers, but has been noted for its discriminating expression between normal and tumor 
cells in chronic lymphocytic leukemia (CLL) (46). Ror1 targeted monoclonal antibodies 
(MAB) have shown efficacy in both melanoma and breast cancer cells inducing apoptosis 
and reduction of cell migration and invasion (47,48). An additional MAB approach coupled 
with immunotoxin targeting Ror1 resulted in a significant increase in apoptosis in Ror1-
expressing CLL cells (49,50). A translation of these MAB approaches for targeting Ror2 
therapeutically has great potential. 
 Dependent upon Ror2’s activity as an RTK, the development of a small molecule 
inhibitor for Ror2 may prove to be very bright avenue. The consistent drawback and 
sometimes saving grace of RTK inhibitors is their lack of specificity due to the highly 
conserved nature of ATP-binding pocket and catalytic loops governing kinase activity 
between kinases (3). However, as the Ror2 kinase domain is marked by a few departures 
from conserved sequences, including a switch from DFG to DLG in the catalytic loop may 
aid in the specificity of any identified small molecule inhibitors of Ror2 (51) (Figure 4.3). 
However, prior to any screening of potential inhibitors of Ror2 additional work is needed to 
further clarify the kinase activity of Ror2. If it is found that Ror2 truly does exhibit intrinsic 
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tyrosine kinase activity then it represents a prime target for the development of small 
molecule inhibitors. 
 
Conclusions 
The research presented within this dissertation describes the function of Ror2 as a 
member of the Wnt signaling network within the context of RCC, and reveals a novel role of 
Ror2 as a mediator of β-catenin-dependent signaling in RCC. Prior studies have 
demonstrated Ror2’s dual role in Wnt signaling and its ability to mediate canonical Wnt 
signaling. However, for the first time we have demonstrated that Ror2 expression 
independent of Wnt3a and LRP6 leads to a poised state of β-catenin-dependent signaling 
via activation of DVL2/3 and stabilization of β-catenin. In addition we have also shown this 
poised state through stabilization of β-catenin required the kinase domain of Ror2.  
Likewise, we more thoroughly examined Ror2’s role in RCC tumorigenesis. Building 
off of previous works we have shown that Ror2 promotes increased cell migration, tumor 
growth, and for the first time, increased tumor vascularity. Finally we have shown the ability 
of Ror2 to serve as an independent prognostic biomarker, with high Ror2 expression in 
patients correlating with a more aggressive disease marked by increased tumor size, 
leading to significant decreases in overall survival. These findings have demonstrated the 
complexity of Wnt/Ror2 signaling in RCC, along with Ror2’s capability to serve as a 
prognostic biomarker and possibly as a predictive biomarker with the advent of Ror2-
targeted therapeutics. 
Following these findings several key aspects of Ror2 signaling need to be addressed 
in order to allow the field to advance. First and foremost is the need to determine if Ror2 
belongs to the class of pseudokinases or is an active RTK. This aspect of Ror2’s catalytic 
activity is central to our understanding of its signaling, its interaction with other proteins, and 
how we can best develop Ror2-targeted therapeutic options for RCC and other cancers. 
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Second, although we have made strides in elucidating Ror2 signaling in RCC, additional 
work is needed to illuminate contextual differences in its signaling. Determination of what 
additional coreceptors or factors are influencing Ror2’s differential signaling among the Wnt 
pathways will provide us a with better understanding of its differences between cancers and 
how these might influence phenotype and clinical outcome. Finally, with our establishing 
Ror2 as a prognostic biomarker in RCC and its known tumor-promoting role in many other 
cancers, there now is a great need for the development of diagnostic assays for Ror2 and 
targeted therapeutics. 
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